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ABSTRACT 
 
CHARACTERIZATION OF HUMAN T-BET-EXPRESSING B LYMPHOCYTES AND THEIR 
ROLE IN THE HIV IMMUNE RESPONSE 
 
James J. Knox 
Michael R. Betts 
 
Humoral immunity is critical for the prevention and control of viral infections, yet the specific B 
cells and mechanisms regulating antiviral responses in humans remain poorly defined. The Th1-
associated transcription factor T-bet coordinates intracellular pathogen immune responses, and 
recent murine studies identified a T-bet-expressing B cell subset that mediates humoral antiviral 
immunity, but an analogous cell population has not been identified in humans. In this study, we 
sought to investigate the role of T-bet-expressing B cells during human viral infections. We 
identified T-bet expression within the memory B cell compartment of healthy individuals and 
described a relationship between the transcription factor and IgG1 and IgG3, two antiviral 
antibody isotypes. The T-bet+ B cell population was comprised of two discrete subsets: T-betlow 
resting memory cells and a highly activated, transcriptionally distinct T-bethigh subset displaying an 
atypical memory phenotype. The T-bethigh cell population transiently expanded in blood following 
vaccination with yellow fever or vaccinia virus; however, these cells were induced and maintained 
at an elevated frequency by chronic HIV viremia and were associated with increased expression 
and secretion of IgG1 and IgG3. The HIV gp140-specific response was maintained almost 
entirely by T-bet+ memory B cells in both viremic and aviremic donors. Together, our findings 
identify T-bet is a critical regulator of humoral antiviral immunity in humans and suggest T-bet+ B 
cells specifically mediate the humoral immune responses to live viral vaccines and HIV. 
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CHAPTER 1	  
 
INTRODUCTION 
	  
	  
	  
1.1 B cells and immunological memory: an introduction 
 
 B lymphocytes, or B cells, were first described as a separate lymphocyte lineage from T 
cells in 1965 by Cooper et al., named as such for their bursa-dependent, versus thymus-
dependent, development in birds (1). A number of seminal studies established B cells as the 
mediators of humoral immunity that give rise to plasma cells and ultimately regulate the 
production of antibodies, soluble γ-globulin proteins that recognize pathogens (2). B cells and 
antibodies are necessary for successful immune responses to various viruses, bacteria, fungi, 
and parasites, mediating pathogen clearance directly by neutralization or in concert with the 
innate and adaptive immune systems (3). The ability to harness humoral immunity through 
vaccination stands as perhaps the greatest public health achievement, as vaccines have greatly 
reduced the incidence of numerous infectious diseases and have eradicated smallpox (4). 
Notably, nearly all licensed vaccines are thought to function primarily through the elicitation of 
protective antibodies and B cell memory (4), highlighting the powerful capacity of the humoral 
immune system to afford protection against invading pathogens.  
  One of the hallmarks of adaptive immunity is its ability to establish long-lived memory 
cells capable of recognizing previously encountered antigens and inducing a focused 
immunological response. Upon activation by their cognate antigens, mature T and B cells give 
rise to a suite of antigen-experienced progeny, including effector cells that mediate the acute 
response and long-lived memory cells that persist as sentinels prepared for re-infection (5). Upon 
antigen re-encounter, memory B cells fulfill several functions that contribute to the immune 
respnose: they are poised to quickly differentiate into antibody-secreting cells, but they also can 
seed new germinal center reactions to further mature their B cell receptor via hypermutation and 
isotype switching, processes that improve antigen binding affinity and increase the diversity of 
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antibody effector functions (6). An improved understanding of B cell biology during the generation 
of humoral immune responses will inform vaccine development and therapeutic interventions to 
strengthen immunity. 
 
 
1.2 Generation of humoral immunity 
 
Early B cell Development  
 The lineages of all antigen-specific B cells can be traced back to the bone marrow. B cell 
development in adults begins in the bone marrow, a niche with specific growth factors such as IL-
7 and other signals necessary to guide the differentiation of hematopoietic stem cells through 
multipotent myeloid/lymphoid progenitor and common lymphoid progenitor stages, and finally into 
the B cell lineage (7). Early B cell progenitors are restricted to the B cell lineage upon 
upregulation of Early B cell Factor 1 (EBF1) and Paired Box 5 (Pax5), two transcription factors 
that function within a broader transcriptional network to regulate the B cell developmental process 
and its stepwise expression and rearrangement of the B cell receptor (BCR) genes (8, 9). B cell 
precursors complete rearrangement of their VH, DH, and JH segments to form the BCR heavy 
(IgH) chain and express it on the surface, where it can signal to promote allelic exclusion and, in 
complex with the surrogate light chain as the pre-BCR, confirm the heavy chain’s ability to 
complex with a light chain (10, 11). Surviving pre-B cells rearrange the VL and JL segments to 
create the light (IgL) chain and finally join the heavy and light chains together to form a functional 
BCR with an IgM constant region (12).  
 Newly formed immature B cells that are sufficiently non-self-reactive will egress from the 
bone marrow into the periphery, where they are termed ‘transitional’ B cells (12, 13). Transitional 
B cells undergo additional selection and maturation processes in secondary lymphoid tissue sites 
such as the spleen, where their survival is dependent upon both BCR signaling strength and 
concentrations of B lymphocyte stimulator (BLyS), a B cell survival factor. Appropriate signal 
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combinations allow transitional B cells to seed the mature naïve B cell compartment (14, 15). The 
resulting mature B cell pool demonstrates extraordinarily diverse antigen recognition potential 
capable of engaging nearly any incoming pathogen or antigen. Naïve B cells, which account for 
nearly half of all B cells in adults, therefore function as a reservoir of diverse BCR specificities 
waiting to encounter their cognate antigen (11). 
 
The initiation of humoral immune responses 
 In lymphoid tissues, naïve B cells recognize and bind their cognate antigen using 
surface-expressed BCR. Antigen binding transduces activation signals via BCR-associated Igα 
and IgΒ molecules containing immunoreceptor tyrosine-based activation motifs (ITAMs) and is 
enhanced by concurrent activation of a co-receptor complex consisting of CD19, CD21, and 
CD81 (16). Phosphorylation of ITAMs by Src-family tyrosine kinases recruits molecules such as 
spleen tyrosine kinase, phospholipase Cγ2, and phosphoinositide 3-kinase to initiate signaling 
cascades resulting in calcium mobilization, transcriptional activation, cytoskeletal rearrangement, 
and internalization of BCR-antigen complexes (17). In vivo, this activation process often occurs in 
the context of B cell-follicular dendritic cell (FDC) interactions and is facilitated by the formation of 
an immunological synapse, a specialized structure concentrating multiple BCR-antigen and 
signaling molecule complexes at the interface between the two cells (16).  
 B cells can subsequently undergo T cell-independent (TI) development, which results in 
production of low-affinity plasmablasts and small numbers of memory B cells, or begin the T cell-
dependent (TD) pathway. The TD activation process continues as B cells process and 
subsequently present internalized antigens on major histocompatibility complex (MHC) molecules 
to cognate T cells at sites such as the border of the T cell and B cell zones or the interfollicular 
zone (17, 18). Here, B cells begin extended interactions with recently activated antigen-specific 
CD4+ T cells and proliferate (19). Several fates are possible following T cell interactions: 1) a 
subset of activated B cells further migrate into extrafollicular regions and give rise to unswitched 
memory B cells or short-lived plasmablasts that produce low-affinity antibodies, while 2) 
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additional B cells begin the germinal center maturation pathway and eventually give rise to high 
affinity memory B cells and plasma cells (19).  
 Both activated memory B cells and CD4+ T cells destined to generate a germinal center 
reaction undergo a differentiation process regulated in part by the transcription factor B cell 
lymphoma protein 6 (Bcl-6; (20)). Alterations in homing receptor expression, including 
upregulation of CXCR5 and downregulation of CCR7, permit the migration of these cells, now 
referred to as germinal center (GC) B cells and T follicular helper (Tfh) cells, into the center of the 
B cell follicle (21, 22). B cells congregate amongst follicular dendritic cells (FDCs), an antigen-
presenting population, proliferate, and eventually form a large structure comprised of light and 
dark zones (23). In the light zone, B cells compete for Tfh cell help: the process is dependent 
upon BCR affinity, as high affinity B cells bind and uptake more antigen from FDCs, and 
internalized antigens are processed and presented via MHC-II molecules to Tfh cells (24). 
Increased antigen presentation correlates with greater Tfh help signaling in the form of cell-to-cell 
contact (i.e. CD40-CD40L interactions) and helper cytokines (i.e. IL-21) that promotes B cell 
survival (19). B cells receiving insufficient Tfh help undergo apoptosis, while B cell clones 
obtaining Tfh help migrate into the dark zone, proliferate extensively, and simultaneously 
introduce point mutations into the antigen binding regions of their BCR (19, 25). B cells can 
migrate back into the light zone for additional Tfh help, and these iterative cycles of competition, 
proliferation, and mutation improve BCR affinity for the antigen and ultimately select for high-
affinity B cell clones (25). Isotype switching, the process of changing the expressed antibody 
class from IgM to alternative isotypes with diverse functions, also takes place within the light zone 
(26). Upon exiting the germinal center, high affinity GC-produced B cells can differentiate into 
memory B cells or antibody-secreting cells (5).  
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1.3 Antibodies and their function 
 
Antibody-secreting cell fate decisions 
 Plasma cells and their immature precursors plasmablasts (collectively termed antibody 
secreting cells (ASCs)) represent the terminal differentiation state of the B cell lineage and 
function to constitutively produce and secrete antibodies (27). During early immune responses, 
these cells derive from activated B cells via a GC-independent mechanism to generate low-
affinity antibodies as a first line of defense. As immune responses develop, longer-lived ASCs 
with high-affinity antibodies are generated by T-dependent germinal center reactions (27, 28). In 
both cases, adoption of the ASC fate requires partial suppression of B cell identity, which is 
achieved by transcriptional repression of Bcl-6 and Pax5 by the transcription factor PR domain 
zinc finger protein 1 (PRDM1, or BLIMP1; (29, 30)). Together with BLIMP1, the transcription 
factors interferon regulatory factor 4 (IRF4) and X box binding protein 1 (XBP1) further promote 
the ASC developmental program and drive plasmablast differentiation (31-33). Plasma cells 
migrate to specific tissues such as bone marrow and gut-associated lymphoid tissue (GALT), 
where they can persist for decades and continue to secrete protective antibody (34, 35).  
 
Antibody structure and function 
 Antibodies (also known as immunoglobulins, or Ig) are globular proteins that exist either 
in a cell membrane-expressed form as the BCR or in a soluble form within serum and at sites of 
pathogen encounter such as mucosal surfaces. Antibodies are comprised of two identical sets of 
heavy chains and light chains connected by disulfide bonds to form a distinctive Y-shape, with an 
antigen binding region (Fab) at the two tips and a constant region (Fc) at the base that interacts 
with immune system components (3). The Fab region contains variable domains with 
complementarity-determining regions (CDRs) that directly interact with antigen, can be highly 
mutated, and are interspersed between framework regions (FRs) that maintain domain structure 
(3). Conversely, the Fc region lacks this mutational diversity but exists in several different isotypes 
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that inform antibody function: IgM, IgD, IgA (two subtypes), IgG (four subtypes), and IgE . 
Modifications such as glycosylation can further influence the functionality of each isotype by 
affecting Fc receptor interactions and antibody half-life (36).  
 The utility of antibodies is based upon their ability to diversify their antigen binding 
domains and switch their isotype classes, two processes that require activation induced cytidine 
deaminase (AID; (37)). Functionally, this B cell-specific enzyme converts deoxycitidine (dC) to 
deoxyuracil (dU) at targeted DNA sites, leading to induction of point mutations that facilitate 
somatic hypermutation or double strand breaks that enable class switch recombination (37, 38). 
AID expression is tightly regulated transcriptionally, post-transcriptionally, and at the protein level 
by a number of factors in an effort to minimize AID activity at off-target genetic loci that could 
cause cell transformation (38). Within the B cell compartment, AID is primarily expressed within 
GC B cells but is upregulated following B cell activation can also be expressed during 
extrafollicular B cell development (39). AID expression is critical for the development of high 
affinity antibodies and memory B cells during immune responses (24, 40).  
 Antibodies function to mediate pathogen clearance in several ways that are directly 
dependent upon AID-regulated somatic hypermutation and class switching. Antibodies can 
directly neutralize pathogens by interfering with processes necessary for infection and 
pathogenesis (e.g. preventing interaction between virions and cell surface receptors necessary 
for viral entry (3)); neutralization is improved with affinity maturation and is generally independent 
of the Fc region (41). Antibodies can also act as intermediaries via opsonization, the marking of 
infected cells or pathogens for death or immune clearance. This process is dependent upon the 
Fc region’s ability to activate the complement system and engage phagocytic cells and natural 
killer cells that express Fc receptors (3, 42, 43). Different types of pathogens elicit specific 
antibody isotypes to mediate relevant effector functions; human antibody isotype diversity will be 
discussed below. 
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Antibody isotypes 
 IgM is the first isotype B cells express during development (17). IgM is generally of low 
affinity, demonstrating reduced rates of somatic hypermutation and increased polyreactivity 
compared to other isotypes. To compensate for this, IgM is secreted in a pentameric complex 
joined together by disulfide bonds to enable high avidity interactions with antigens (3). IgM is the 
first serum antibody produced during an acute infection before germinal centers are fully 
established; however, significantly mutated IgM can be produced by germinal center-derived 
memory B cells and plasma cells later in the response (44). Functionally, IgM antibody can 
opsonize antigens and efficiently activates the complement system, and evidence in humans 
suggests a niche for IgM+ memory B cells in seeding secondary germinal center reactions at the 
expense of undergoing plasma cell differentiation upon antigen re-encounter (45). Thus, IgM 
plays an important role at multiple points during the course of both primary and secondary 
infections.  
 The biological function of IgD remains unclear, as it is rarely secreted into the serum. 
During development, IgD is first detected on naïve B cells, where it is co-expressed with IgM (17). 
A recent study suggests IgD may chiefly function in a signaling capacity as a BCR on naïve cells, 
as it recognizes multivalent antigens more efficiently than the IgM isotype (46). However, a 
number of observations suggest wider roles for this antibody isotype: most IgM-expressing 
memory cells continue to co-express IgD (6), class-switched IgD+ memory B cells (“IgD-only”) can 
be found in peripheral blood at low frequencies (47), IgD+ plasma cells have been identified in 
tonsils and the human upper airway (48), and secreted IgD has been shown to bind and activate 
basophils (48). 
 IgA antibodies are critical components of mucosal immunity that can be secreted in a 
dimeric structure. While detectable in serum at a titer equal to or greater than IgM, IgA is the most 
prevalent isotype at mucosal surfaces and in secretions (3). The IgA class is comprised of IgA1 
and IgA2 subtypes that differ structurally in their hinge regions, with IgA1 being prevalent in 
serum and IgA2 in secretions. Plasma cells in GALT constitutively produce IgA that can be 
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transported across intestinal epithelial cells via the polymeric Ig receptor into the lumen, where it 
protects the epithelium from infection and regulates commensal bacteria populations (49). 
Functionally, IgA mediates neutralization but does not efficiently activate complement or opsonize 
antigens (3). 
 IgE mediates immune responses to helminths and plays a role in allergic responses. 
While serum IgE levels and frequencies of IgE+ memory B cells in peripheral blood are low, IgE is 
a potent activator of mast cells and basophils, which express the high affinity FceRI (50). The 
interaction of FceRI-bound IgE with antigen leads to degranulation and release of inflammatory 
mediators from mast cells that exacerbate allergic reactions (50). IgE also binds to a low affinity 
FceRII receptor expressed on B cells, through which it regulates antibody production (51).  
 IgG class antibodies are the most prevalent in human serum, in part due to their long half 
life. There are four subtypes, named in order of abundance (IgG1>IgG2, etc.), with distinct 
structural and functional profiles (52). IgG1 and IgG3 are induced by protein antigens, particularly 
in the context of a TD response, and are notable for their ability to engage effector cells: they 
efficiently activate complement and bind to all three classes of FcγRs, although IgG3 generally 
has higher affinity (3, 6, 52). As such, IgG1 and IgG3 isotypes are critical for antiviral responses 
and are particularly inflammatory (52). IgG3 is produced during the early immune response to 
viral infections and is eventually overshadowed by IgG1 as the response progresses (53, 54); the 
gradual loss of IgG3 is based upon the structure of the Fc region locus (i.e. IgG3+ memory cells 
can switch to become IgG1+, but not vice versa) and IgG3’s reduced half-life compared to other 
IgG isotypes (IgG1 outcompetes IgG3 for neonatal Fc receptor-mediated recycling (53)). In 
contrast, IgG2 is critical for polysaccharide antigen responses, as evidenced by the association 
between IgG2 deficiency and increased susceptibility to encapsulated bacteria infections. IgG2 is 
often produced during TI immune responses, but many IgG2+ memory B cells show evidence of a 
germinal center origin (55, 56). IgG4 is a rare isotype that can be induced in a number of settings, 
including polysaccharide antigen responses and settings of allergy (52). IgG2 and IgG4 poorly 
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activate complement and have low affinity for most FcγRs; as such, they are relatively inefficient 
opsonizers compared to the IgG1 and IgG3 isotypes (3).  
 
 
1.4 Memory B cells 
 
Memory B cell fate decisions  
 Like ASCs, memory B cells can also differentiate from T cell-independent (TI) or T cell-
dependent (TD) immune responses, having either extrafollicular or germinal center origins in the 
latter case (5). However, in contrast to ASCs, the molecular mechanisms regulating adoption of 
memory B cell fate after germinal center exit are largely unclear. While a master transcription 
factor akin to BLIMP-1 has not been identified, the transcriptional regulator BTB Domain and 
CNC Homolog 2 (Bach2) may be important for memory differentiation (57, 58). Survival of the 
germinal center reaction in the absence of ASC-inducing signals has also been proposed to 
inherently promote assumption of the memory fate (59), and events predating this fate choice 
such as isotype class switching may even affect memory differentiation (60). Regardless, the 
memory B cell compartment functions as a reservoir of cells primed to respond to pathogen re-
encounter, orchestrating a rapid secondary response culminating in antibody production to 
contain and clear the pathogen before widespread pathology can occur.  
 The memory B cell compartment is exceptionally diverse, a property reflected not only in 
its expression of the different antibody isotypes, but also in the various origins, functions, and 
phenotypes of its members. Despite this diversity, these cells are reliably identified by the 
presence of antibody somatic hypermutation, isotype switching, and phenotypic signatures 
associated with a post-germinal center state (6). In this dissertation, “memory B cells” will broadly 
refer to the antigen-experienced B cells produced by immune responses that maintain the B cell 
phenotype (i.e. excluding ASCs): this group includes both long-lived, quiescent cells and those 
actively participating in the immune response. 
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Memory B cell functions 
 Memory B cells fulfill a number of roles that both support developing immune responses 
and contribute to pathogen clearance. The ability to readily differentiate into plasmablasts 
producing high-affinity antibodies separates memory from naïve B cells and is perhaps the most 
important function of B cell memory (6). Memory B cells can also re-enter and form new germinal 
center reactions upon pathogen re-encounter, a process that diversifies the antigen-specific 
antibody pool by further fine-tuning antibody affinity and broadening the isotype repertoire (61). 
Via these mechanisms, memory B cells can increase the baseline volume of antibody produced 
by existing plasma cells from the primary response and diversify the Fab region to facilitate 
responses to mutating pathogens. 
 Memory B cells also contribute to the immune response with antibody-independent 
functions. B cells highly express MHC-II molecules, which they use to present processed 
antigens to CD4+ T cells (16). Antigen presentation is an important feature of GC B cells that 
facilitates interactions with Tfh cells in germinal centers to promote mutual activation, 
proliferation, and differentiation (62), and subsets of post-germinal center B cells appear to be 
efficient antigen presenters in specific tissue sites such as the mouse spleen (63). Memory B 
cells also produce cytokines that shape the immune response: B cells can produce IL-12 and 
IFNg, which promote Th1-type (intracellular pathogen) immune responses, or IL-4 and IL-13, 
which promote Th2-type (extracellular parasite) immunity (64, 65). B cells produce additional 
cytokines such as tumor necrosis factor and IL-6, and a subset of B cells, termed regulatory B 
cells, produce the cytokines IL-10 and/or transforming growth factor beta to suppress immune 
responses (66).  
 
Human memory B cell phenotypes 
 Memory B cells are derived from naïve B cells following antigen-induced activation, 
leading to the accumulation of mutations in antibody variable domains and (in some cases) 
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switching from the IgM+IgD+ isotype. Memory B cells were originally identified by the IgD- 
phenotype (67) until the discovery of somatically mutated IgD+ B cells suggested that isotype 
expression was insufficient to delineate memory (68, 69). A correlation between somatic mutation 
and CD27 expression was concurrently described, identifying CD27, a tumor necrosis factor 
receptor family member, as a B cell memory marker in the spleen and peripheral blood (68, 69). 
Appropriately, CD27+ B cells were found to be larger, contained increased cytoplasm, and readily 
differentiated into class-switched ASCs following antigen and/or cytokine stimulation (70).  
 Subsequent studies would identify memory B cell subsets that do not express CD27. 
First, a peculiar CD27- population expressing Fc receptor homologue 4 (FcHR4, now referred to 
as FcRL4) was described in human tonsil, with comparable somatic mutation and activation 
marker expression to classical tonsilar memory B cells (71). CD27-IgG+ populations were also 
identified in the peripheral blood, comprising 25% of total IgG+ B cells (72); these CD27-IgG+ cells 
phenotypically and morphologically resembled their CD27+ counterparts, albeit with slightly 
reduced somatic mutation frequencies and enrichment for the IgG3 isotype (72, 73). Subsequent 
analyses of replication history and antibody maturation suggested associations between memory 
B cell phenotype and origin: CD27+IgM+ and CD27-IgG+ likely derive from primary germinal center 
reactions, while CD27+IgG+ and CD27+IgA+ cells develop from secondary reactions and CD27-
IgA+ cells mature extrafollicularly (44). In another study, CD27+ and CD27- class-switched 
memory cells showed a genealogical relationship but CD27 expression was not specifically 
associated with product or precursor cells (55). Together, these studies used evidence of somatic 
hypermutation, clonal expansion, and/or specificity to previously encountered pathogens to 
establish the existence of CD27- memory B cells.  
 The origin and identity of human IgM+ memory B cells, a population divided into 
IgM+IgDlow/- (“IgM-only”) and IgM+IgD+ subsets, remains a subject of debate. IgM-only cells 
appear to be germinal center-derived and clonally related to class-switched CD27+ memory B 
cells (74). Conversely, IgM+IgD+ cells were initially proposed to be either naïve cells with pre-
immune antibody mutations, TI response-derived cells, or the circulating counterpart of the 
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splenic marginal zone B cell population (6, 74, 75). However, a number of studies identified 
characteristics suggesting a germinal center-dependent origin for significant portions of the 
IgM+IgD+ pool, which molecularly, phenotypically, and functionally resemble IgG+ memory B cells 
(6, 45). Taken together, IgM+IgD+ memory B cells are likely a heterogeneous population with 
multiple origins and biological niches. 
 
Signals regulating memory B cell heterogeneity 
 The differentiation fate of activated naïve B cells (and potentially re-activated memory B 
cells) is impacted directly by pathogen-derived molecular signals and cytokines produced by 
various immune and non-immune cells in response to the infection (64, 76). Via this process, 
specific infection cues shape the character of the subsequent antigen-specific memory B cell 
response and ultimately generate a diverse pool of memory B cells. Murine studies indicate that B 
cell differentiation can occur in a polarized way, analogous to CD4+ T cell polarization, in a 
process largely dependent upon cytokines: IFNg drives Th1-like differentiation in B cells, while IL-
4 drives Th2-like differentiation patterns (64, 77). These polarized B cells subsequently produce 
signature cytokines associated with their respective immune response types, undergo specific 
patterns of antibody isotype class switching, and are imprinted with a trafficking receptor profile 
(65, 78, 79).  
 B cells further depend upon toll-like receptors (TLRs), innate sensors of pathogen-
associated molecular patterns, to generate appropriate humoral responses. Naïve B cells only 
express TLRs at low levels, but human memory B cells can express TLRs 1, 2, 6, 7, 9, and 10: 
TLRs 1, 2, an 6 are plasma membrane-expressed and recognize bacterial antigens, while TLRs 
7, and 9 are expressed in endosomes and recognize nucleic acids (TLR10’s function is unclear 
(76)). TLRs are upregulated by cell activation and, by synergizing with BCR and CD40 
stimulation, can further promote B cell activation and influence differentiation (80). TLR signaling 
is critical at multiple stages of B cell development, as GC B cells are particularly sensitive to TLR 
signaling and plasma cell differentiation directly depends on TLR activation (81-83). Deletion of 
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TLRs or TLR-associated signaling molecules such as MyD88 in mice have been shown to 
diminish the magnitude or quality of antibody responses against protein immunogens, viral-like 
particles, and live replicating pathogens, directly demonstrating the impact of TLR-signaling on 
developing humoral responses (76). Together, cytokine and TLR stimulation are transduced by a 
number of signaling pathways that culminate in the activation of transcription factors to 
subsequently alter gene expression. 
 
Memory B cell migration and tissue distribution 
 Memory B cells utilize peripheral blood and the lymphatic system to traffic toward 
lymphoid and non-lymphoid tissues where antigen encounter is most likely. Memory B cells have 
been identified at mucosal sites, such as the gut and lungs, in the skin, in various lymphoid 
tissues, and can be readily recruited to sites of inflammation (6, 84-86). The directed migration of 
lymphocytes into tissues is dependent upon the processes of chemotaxis, the movement of cells 
toward a chemokine gradient, and cell adhesion. Memory B cell subsets can be targeted toward 
anatomical sites by expression of specific chemokine receptors and adhesion molecules; for 
example, gut homing requires expression of the α4β7 integrin and the chemokine receptor CCR9, 
whereas skin homing involves cutaneous lymphocyte antigen and contributions from chemokine 
receptors CCR4, CCR6, and CCR10 under different conditions (84, 85). 
 Lymphocyte entrance into and exit from lymph nodes is perhaps the best described 
trafficking process (87). B and T cells enter into lymph nodes via afferent lymph or from blood via 
high endothelial venules (HEVs), and entry is highly dependent upon adhesion molecule 
interactions: lymphocyte-expressed CD62L interacts with HEV-expressed addressins, causing 
the cells to slow down, roll along the endothelial surface, engage endothelial ICAM1 and ICAM2 
adhesion molecules via lymphocyte function-associated antigen 1, and extravasate between 
endothelial cells into the lymph node parenchyma (87, 88). Chemokine receptors such as CXCR5 
and CCR7 also support lymph node entry and further guide B cell localization within the lymph 
node: CXCR5 signaling induces B cells and Tfh cells to traffic into B cell follicles, B cell-rich areas 
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in which TD humoral responses are initiated and matured via the germinal center reaction (21, 
22). T cell cortex surrounds these follicles, and CCR7 positions B cells near the T cell border to 
facilitate B-T cell interactions (19). B cells leaving the lymph node emigrate into the lymphatic 
system following a sphingosine 1-phosphate (S1P) gradient, from low concentrations in lymph 
node parenchyma to high blood and lymph concentrations (89). Recent emigrants can travel to 
and survey additional lymph nodes or enter the blood circulation via the thoracic or right lymphatic 
ducts (90).  
 The spleen is a unique lymphoid organ optimized for blood-borne pathogen responses. 
Spleen is comprised of two main compartments: white pulp, with a T cell zone and B cell follicles 
that resembles lymph node structure, and red pulp, a macrophage-rich site that filters the blood 
(91). In humans, follicles are surrounded by a two-layer marginal zone, which contains a specific 
B cell subset termed marginal zone (MZ) B cells, and a perifollicular zone that further separates 
the MZ and red pulp (91). Peripheral blood lymphocytes enter the spleen via splenic arterioles 
that empty into the open circulation of the perifollicular zone, and these cells can subsequently 
traffic into white pulp in a CCR7 or CXCR5-dependent manner or into the red pulp’s splenic 
sinuses to exit the spleen along an S1P gradient (21, 22, 87, 91). Due to differences in structure 
and cell composition between rodents and humans (i.e. lack of specific macrophage populations 
in human splenic marginal zone), the mechanisms of blood sampling and antigen delivery to 
human MZ B cells are unclear (92); however, MZ B cells are important for TI responses to blood-
borne pathogens such as encapsulated bacteria and can quickly differentiate into plasmablasts 
upon antigen encounter (6). Additionally, MZ B cells function to connect the innate and adaptive 
immune systems by shuttling between the marginal zone and B cell follicles in an S1P-dependent 
manner to deliver antigens for initiation of follicular responses (93). Unlike rodents, human MZ B 
cells are somatically mutated and therefore represent a memory population (92). It is unclear if 
human MZ B cells can traffic into the periphery or are spleen-restricted (6). 
 Since cell tracing is difficult in humans, it is often unclear whether B cells identified within 
human peripheral tissues are transiently surveying for pathogens or reside permanently within 
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these tissues. The concept of resident memory cells, specific subsets that remain in tissues and 
do not re-circulate, is well described in the T cell literature but is poorly understood in the context 
of B cells. To maintain tissue residence, T cells rely on integrins and other receptors to mediate 
adhesion and actively inhibit egress mechanisms (94). Resident memory T cells (TRM) 
characteristically express CD69, a C-type lectin that inhibits sphingosine 1-phosphate receptor 1 
(S1P1)-regulated egress, and CD103 (αE integrin), which complexes with β7 integrin to mediate 
epithelial cell adhesion (94, 95). While definitive B cell tissue residence markers have not been 
defined, lymphocyte circulation studies in sheep indicate that specific subsets of B cells do not re-
circulate (i.e. are not found in lymph) and likely remain in tissues (96). Plasma cells generally do 
not re-circulate and are resident in bone marrow and gut lamina propria (34, 35). 
 
 
1.5 The transcription factor T-bet 
 
T-bet in immunity 
 The T-box transcription factor family includes a number of genes critical for regulation of 
developmental processes (97). Named after the Brachyury, or T gene, family members 
characteristically contain a highly conserved, 180 amino acid T-box DNA binding domain (98). In 
2000, Szabo et al. discovered a novel family member within T cells, which they termed T-bet (T-
box expressed in T cells (99)). T-bet was first described as a critical regulator of naïve CD4 T cell 
differentiation into the T helper 1 (Th1) lineage, but subsequent studies have identified the 
importance of this transcription factor in regulating development and effector functions of various 
immune cell types, including CD8 T cells, NK cells, B cells, dendritic cells (DCs), and monocytes 
(100). T-bet is expressed exclusively within the immune system where it promotes type 1 (Th1) 
immunity against intracellular pathogens (100).  
 T-bet is critical for driving both innate and adaptive Th1 responses. Monocytes and DCs 
are induced to express T-bet by IFNg stimulation, and DCs require this intrinsic T-bet expression 
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to appropriately prime Th1 CD4+ T cells and shape the subsequent adaptive immune response 
(101, 102). Innate lymphoid cells, NK cells, invariant NKT cells, and γδ T cells, separate lineages 
of innate-like lymphocytes, require T-bet at various developmental checkpoints and to drive 
effector functions such as IFNg production (100). Th1 CD4+ T cell development and IFNg 
production also require intrinsic T-bet expression, and forced expression of T-bet in Th2 and 
Th17 cells reverts these cells to a quasi-Th1 phenotype (99). CD4+ T cells lacking T-bet cannot 
mount Th1 responses and fail to control intracellular bacterial infections (99, 103). T-bet is also an 
important regulator of CD8+ T cell development and effector functions, although it works 
cooperatively and often redundantly with the T-box family member Eomesodermin (Eomes (104, 
105)). T-bet seems to be particularly important for early production of cytolytic proteins, such as 
granzyme B, and IFNg, during CD8+ T cell responses, and subsequent Eomes induction can 
support and compliment these effector functions (100). Conversely, memory differentiation is 
regulated differentially by T-bet and Eomes: T-bet promotes terminal differentiation into the 
effector phenotype, while Eomes promotes the formation of central memory CD8+ T cells (100). 
Combined T cell receptor stimulation and signaling from inflammatory cytokines such as IFNg or 
IL-12 promote T-bet expression in T cells (99, 106). 
 Mechanistically, T-bet functions both as a transcriptional activator to support Th1 identify 
and a repressor to prevent the adoption of alternative lineage fates. T-bet actively promotes 
expression of genes associated with the Th1 phenotype, such as Ifng and Cxcr3, and T-bet can 
drive similar gene expression programs between different lineages by binding the same gene 
targets in each cell type (107). However, T-bet also can promote separate lineage-specific Th1-
associated programs in different immune cells (e.g. cytolytic potential in CD8+ T cells but not B 
cells (100)). To support gene expression, T-bet recruits cofactors such as Runx3 for activation of 
the Ifng gene and chromatin remodeling complexes to open target loci (108). For repression, T-
bet similarly recruits Bcl-6, a transcriptional repressor, and exploits its repressive function to 
silence specific non-Th1 genes (109). T-bet can also indirectly repress alternative lineage 
development by binding to and inactivating GATA3 (Th2 differentiation) and Runx1 (activator of 
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Rorc, which promotes Th17 differentiation (108)). These diverse gene regulation mechanisms 
combine to support Th1 cell identity across the immune system. 
  
T-bet in B cells 
T-bet expression was first identified in mouse B cells by Glimcher et al., who found that 
T-bet regulates IFNg production by B cells following Th1 cytokine (IL-12, IL-18) and CD40 
stimulation (99). This B cell-produced IFNg was suggested to play an important 
immunoregulatory role by promoting Th1 CD4 T cell development, and, in an analogous way, 
autocrine Th1-type polarization of B cells (64) (65).  However, subsequent studies identified 
perhaps the most important B cell-specific function of T-bet: regulation of antibody isotype 
switching to the IgG2a/c isotype (78) (110), the signature antibody isotype of humoral Th1-type 
immune responses (111). Following completion of isotype switching, IgG2a+ memory B cells and 
plasmablasts continue to depend on T-bet for their survival and functionality (112). Altogether, T-
bet appears to function as a Th1 master regulator within the B cell compartment of mice by 
controlling the early development of IgG2a+ B cells from naïve precursors and actively 
maintaining the integrity of mature IgG2a+ memory B cells.  
The roles of T-bet in regulating IFNg production and IgG2a class switching suggest that 
this transcription factor primes B cells for antiviral responses. Early in vitro studies of cytokines or 
other factors promoting B cell T-bet induction, such as IL-12, IL-18, and anti-CD40 stimulation, 
have further supported this hypothesis (99). Subsequent studies have additionally identified IFNg 
and IL-21 as potent inducers of T-bet expression and IgG2a isotype switching in B cells, 
particularly when paired with TLR7 or TLR9 stimulation (78, 110, 113-116). As viral nucleic acids 
can stimulate TLR7 and/or TLR9, and IFNg and IL-21 are produced by the immune system in 
response to viral infections, these experiments suggested that viral infection would be ideal for 
development of the T-bet+ B cell subset. 
Despite this suggestive body of work, T-bet+ B cell involvement in specific antiviral 
responses was not directly demonstrated until several years later. Using the gamma herpes virus 
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68 mouse model of viral infection, Rubtsova et al. showed that T-bet+ B cells acutely expand, 
produce anti-ghv68 antibodies, and are necessary to control viremia to low levels (117). More 
recently, Barnett et al. (2016) used inducible B cell-specific T-bet knockout mice to show that T-
bet+ B cells are critical for maintaining control of chronic lymphocytic choriomeningitis infection, 
through both virus-specific IgG2a production and antibody-independent functions (118). By 
connecting viral loads to the presence of this population, these studies together have established 
T-bet+ B cells as an antiviral subset, with a direct role in controlling multiple murine viral 
infections. 
 In humans, T-bet expression has been identified in peripheral blood B cells specifically 
within the context of inflammatory diseases, including systemic lupus erythematosus (SLE), 
Crohn’s disease, multiple sclerosis, and chronic hepatits C virus (HCV) infection (119-122). In 
lymphoid tissue, a subset of B cells termed monocytoid B cells normally express T-bet, and 
widespread T-bet expression is detectable in B cells within Th1-type reactive lymphoid tissue 
lesions and also several neoplastic lesions (123-125). T-bet’s induction in human B cells under 
pathologic, inflammatory conditions raises the question of whether T-bet expression is aberrant or 
a normal transcriptional regulator of human B cells.  
 
 
1.6 B cells and HIV infection 
  
HIV and immunopathogenesis 
 The first description of what would later be recognized as acquired immune deficiency 
syndrome (AIDS) was made in 1981 with the observations of several homosexual men infected 
with Pneumocystis carnii (126) and developing Kaposi’s sarcoma (127). The subsequent 
identification of a novel retrovirus by multiple groups led to the characterization of the human 
immunodeficiency virus (HIV (128)). HIV is a single-stranded RNA virus that binds to and enters 
immune cells using CD4 and a co-receptor (commonly the chemokine receptors CCR5 or CXCR4 
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(129)). HIV characteristically infects and kills CD4+ T cells, leading to the significant loss of CD4+ 
T cell numbers and progressive immunopathology culminating in AIDS and death (130). HIV 
remains a global health crisis over 30 years after its initial discovery as the causative agent of 
AIDS, with over 30 million individuals infected and nearly 2 million deaths per year attributed to 
the infection (131). Attempts to create an HIV vaccine have largely failed due to the virus’ 
extraordinary antigenic diversity driven by high mutation and replication rates and its ability to 
induce systemic immunopathology. 
 Following transmission and an eclipse phase when virus is undetectable in the blood, 
excessive viral replication produces an acute peak in HIV viremia and concomitant loss of CD4+ T 
cells (132). This depletion results in diminished help to B cells and CD8+ T cells, negatively 
impacting the development of both humoral and cellular immunity to HIV (133). CD4+ T cell 
depletion in the GALT is particularly prevalent, and this process contributes to loss of mucosal 
barrier integrity, microbial translocation, and subsequent systemic inflammation that further 
impairs HIV immunity (134). Following peak viral load, HIV viremia is subsequently controlled to a 
set point by CD8+ T cell-dependent mechanisms (135). Since cellular and humoral immune 
responses are unable to achieve viral clearance, most infected individuals maintain a steady state 
of viremia asymptomatically for years until CD4+ T cell numbers further decline and leave 
individuals susceptible to opportunistic infections (133). HIV disease is characterized by chronic 
viral replication and immune activation that impairs the functionality of all major immune subsets 
(133).  
 
The HIV Env antibody response 
 HIV infection elicits a strong humoral response against a number of viral proteins, with 
antibodies targeting Env, the HIV surface glycoprotein, mediating the majority of antiviral effects. 
IgM isotype antibodies emerge first during early acute HIV infection and recognize gp41, the 
membrane bound Env subunit critical for mediating membrane fusion. These gp41 antibodies 
subsequently undergo class switching to IgG and IgA but remain largely ineffective (136). 
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Similarly, antibodies specific for a number of epitopes on gp120, the cap of Env that binds CD4 
and co-receptors, begin to appear in a sequential manner approximately 4 weeks after infection 
but rarely mediate neutralization (136-139). Autologous HIV neutralizing antibodies targeting Env 
variable regions first appear 4-12 weeks after infection but are unable to neutralize current viral 
quasispecies (54). A number of studies demonstrate that HIV Env-specific neutralizing antibodies 
directly drive Env mutation, and some individuals mount early neutralizing responses that 
significantly pressure the virus (137, 140); however, a situation develops in most chronically 
infected individuals where the generation of Env sequence diversity greatly outpaces autologous 
neutralization development, thereby preventing antibody-mediated clearance of HIV (54). 
 In recent years, technological advances have enabled the isolation and characterization 
of multiple classes HIV broadly neutralizing antibodies (bNAbs (141)). Unlike typical Env-specific 
antibodies, bNAbs demonstrate significant neutralizing capacity against diverse heterologous 
viruses (142). These antibodies develop in a subset of chronically infected individuals only after 
years of infection, suggesting their maturity requires prolonged viremia and/or immune activation 
(143). These antibodies function by targeting sites of weakness on the Env protein, including the 
CD4 binding site, membrane proximal external region, gp120-gp41 interface, and V1-V2 glycan, 
and are further characterized by abnormal features such as long complementarity determining 
region 3 (CDR3) regions, excessive somatic hypermutation levels, and increased autoreactivity 
(143, 144). While bNAbs arise late in the course of infection and are unable to neutralize 
concurrent dominant HIV variants in the infected individual, their development indicates that the 
human body is capable of producing antibodies that can neutralize genetically diverse strains of 
HIV.  
 
B cell hyperactivity and subset alterations 
From the earliest descriptions of HIV infection, B cell hyperactivity was evidenced in 
viremic individuals by lymphadenopathy, hypergammaglobulinemia, and increased activation 
marker expression, cell turnover, and cell death (145, 146). The B cell compartment is 
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significantly impacted by HIV infection, demonstrating drastic alterations in cell phenotype, 
functionality, and the representation of particular subsets (146). Many of these changes are due 
to the effects of excessive infection-induced cytokines and viral replication products on B cells 
and other immune cells that regulate B cell development (147). Hyperactivation and many of the 
B cell subset imbalances can be normalized by lowering immune activation with antiretroviral 
therapy (ART); however, ART-treated individuals exhibit instances of deficient humoral recall 
responses and an incomplete restoration of resting memory B cell numbers by ART, suggesting 
that chronic viremia irreversibly depletes a portion of humoral memory either directly or indirectly 
through the loss of CD4+ T cell help (146, 148). These HIV infection-induced perturbations may 
impede the development and maintenance of protective B cell and antibody responses, 
contributing to chronic persistence of the virus in untreated individuals. However, it is important to 
note that HIV infection does elicit a strong and evolving humoral response that places 
immunological pressure on the virus (137, 138).  
 The peripheral B cell compartment in HIV-infected individuals is significantly altered 
compared to HIV- individuals, with observable differences in the representation of nearly every 
subset (147). Transitional B cells, recent immature bone marrow emigrants detectable at a low 
frequency in healthy individuals, are increased in number as a result of CD4+ T cell 
lymphocytopenia and increased IL-7 levels (149). The inflammatory environment of HIV infection 
is thought to drive polyclonal B cell activation and terminal differentiation and to promote memory 
B cell apoptosis; as such, decreases in naïve and resting memory B cells and increased 
plasmablast numbers are commonly observed (147). Viremic HIV infection is also associated with 
the expansion of atypical memory B cells, subsets present at low to undetectable levels in healthy 
individuals that can be identified by a loss of CD21 expression. These cells are commonly 
subsetted and defined as activated (CD21-CD27+) and tissue-like memory (CD21-CD27-) B cells, 
and the latter has been described as “exhausted” due to its low proliferative capacity following 
BCR (150, 151).  
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The B cell response to HIV  
Many aspects of the HIV-specific B cell response are poorly understood, due to the historical lack 
of cell identification technologies and the field’s general emphasis on studying antibodies (147). 
Recently, HIV Env probes were developed to enable flow cytometric sorting of virus-specific 
memory B cells for cloning of HIV-specific antibodies (152, 153). This process is commonly used 
for the identification and characterization of bNAbs from infected individuals, but these probes 
also afford the opportunity to assess characteristics of the HIV-specific memory B cell 
compartment itself. Studies of HIV-specific B cells during acute infection are lacking since 
individuals are rarely diagnosed before the chronic phase of infection, but HIV Env probe-based 
work suggests much of the early gp41-focused IgM isotype antibody response is generated from 
cross-reactive, commensal bacteria-specific B cells (154). Interestingly, analyses of chronically 
infected individuals found that HIV-specific responses are concentrated in activated and tissue-
like memory B cells instead of classical memory B cells, a phenomenon often interpreted to 
reflect immune dysfunction (155). However, the detrimental impact of an atypical memory cell-
biased (versus classical memory-biased) response has not been directly demonstrated, and the 
mechanisms shifting HIV-specific B cell development into the atypical memory path are unclear. 
 
 
1.7 Thesis goals 
 
Complex viruses such as influenza and HIV have moved the vaccinology field from its empirical 
roots into a new era of rational-based vaccine design requiring careful characterization of 
protective immune correlates. To this end, identification of the mechanisms regulating human 
antiviral B cell responses will provide biomarkers to assess the immunogenicity of vaccine 
candidates and molecular targets for intervention to improve vaccine-induced immune responses. 
Despite significant advances in antibody characterization, factors regulating antiviral humoral 
immunity and the specific B cells mediating acute responses remain undefined. As such, the goal 
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of this thesis was to better define the cells and mechanisms that promote humoral antiviral 
responses by characterizing T-bet’s role in the human B cell compartment and assessing T-bet+ 
B cells’ involvement in the HIV immune response
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CHAPTER 2 
	  
IDENTIFICATION AND CHARACTERIZATION OF HUMAN T-BET-EXPRESSING B 
LYMPHOCYTES 
 
2.1 Summary 
 
Humoral immunity is critical for viral control, but the identity and mechanisms regulating human 
antiviral B cells are unclear. Here, we characterized human B cells expressing the transcription 
factor T-bet and analyzed their dynamics during live viral vaccinations. T-bet+ B cells, a relatively 
small component of the peripheral B cell compartment in healthy individuals, demonstrated a 
memory phenotype and were enriched for the antiviral immunoglobulin isotypes IgG1 and IgG3. 
We identified T-bethigh and T-betlow B cell subsets with divergent phenotypic profiles and 
responses to vaccination: T-bethigh cells were highly activated, transcriptionally distinct from 
resting memory B cells and plasmablasts, and expanded acutely and transiently following yellow 
fever and vaccinia virus vaccinations. Conversely, T-betlow cells displayed a resting phenotype 
and were unresponsive to acute viral infection in most donors. T-betlow cells were readily 
identified in peripheral blood, lymphoid tissues, and in thoracic duct fluid, while T-bethigh cells were 
found primarily in the peripheral blood and in low numbers within the spleen. Together, these 
findings suggest T-bet regulates antiviral immunoglobulin isotype switching and development of a 
distinct T-bethigh B cell subset that is responsive to viral replication and/or inflammatory signals in 
healthy individuals.   
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2.2 Introduction 
 
The humoral immune system is critical for control of multiple viruses during both acute and 
chronic phases of infection (118, 156), and most effective vaccines are thought to function by 
eliciting a protective humoral response (4). Humoral immunity is coordinated by memory B cells, 
antigen-specific subsets that can regulate the developing immune response via functions such as 
antigen presentation, cytokine production, or differentiation into antibody-secreting cells (62, 157, 
158). Memory B cells can also express different antibody isotypes which fulfill diverse 
spatiotemporal and pathogen-specific roles upon secretion (6, 52). Heterogeneity has been 
demonstrated within the origins, development, and functional capacity of human memory B cell 
populations differentiated by a variety of cell surface markers (6). Recent studies have begun to 
assess the contributions of divergent B cell subsets during active immune responses using 
antigen-specific probes (155, 159), but the identity and regulation of memory B cells responding 
to active human viral infections remain poorly understood.  
 Recently, several studies have identified atypical memory B cells as bona fide antigen-
experienced subsets (44, 55, 72, 73, 151). These cells differ from classical memory B cells by 
their activated phenotype (151) and/or absence of CD27 expression (44, 55, 72, 73), a traditional 
marker of B cell memory (68, 69), but show evidence of a germinal center origin based upon 
antibody isotype switching and somatic hypermutation (44, 55, 72, 73, 151). Atypical memory B 
cells have subsequently been described in the context of chronic inflammatory settings in which 
they are abnormally expanded (73, 121, 151, 160-163), and their refractory response to normal B 
cell receptor stimulation has led to the hypothesis that they are an anergic byproduct of excessive 
inflammation (151, 162). However, the immunological role for these populations is unclear.  
Transcription factors are critical regulators of memory B cell identity and function that can 
translate pathogen-specific cues into induction of appropriate humoral responses (76, 112, 113, 
164). Recent studies identified the immune cell-specific transcription factor T-bet as a critical 
regulator of murine antiviral B cell responses (117, 118). T-bet was originally described to control 
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CD4+ Th1 cell development and functionality (99), but T-bet also plays a role in B cell 
differentiation (64, 78). In mice, T-bet expression is required for isotype switching, functionality, 
and survival of IgG2a/c+ memory B cells (78, 110, 112) and can also regulate the expression of 
the antiviral cytokine IFNg and the inflammatory homing receptor CXCR3 in this population (65, 
79). Several groups recently examined the direct role of T-bet+ B cells during murine viral 
infections: gamma herpes virus 68 induces an expansion of T-bet+ B cells, the absence of which 
leads to infection exacerbation (117). Similarly, chronic lymphochoriomeningitis (LCMV) viremia is 
controlled to low levels only in the presence of T-bet+ B cells via a chiefly IgG2a-dependent 
mechanism (118). B cells expressing either TBX21 transcript or T-bet protein have been 
described in the context of autoimmune diseases, chronic hepatitis C infection, and malaria 
infection (120, 121, 162, 165, 166), but the biological niche of this population in healthy humans 
has not been defined.  
 In this study, we characterize the phenotypic and transcriptional profiles of human T-bet+ 
B cells and examine their dynamics during acute human viral infections. We identified T-bet+ B 
cells in healthy human peripheral blood as an antigen-experienced population that demonstrates 
a potentially antiviral phenotype. Unlike T-bet- memory B cells, a subset of T-bet+ B cells is 
activated and transiently expands in response to acute viral infections. Our data identify T-bet 
induction in the B cell compartment by human viruses and suggest that T-bet+ B cells participate 
in the antiviral response. 
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2.3 Results 
 
2.3.1 Human peripheral blood B cells can express the Th1 transcription factor T-bet 
 
Human T cells and NK cells express the Th1 transcription factors T-bet and Eomesodermin 
(Eomes), which regulate cell differentiation and effector functions (100, 167-170). We set out to 
identify B cells expressing these transcription factors in healthy individuals and to compare 
expression levels to other peripheral blood mononuclear cells (Figure 1A). While a relatively low 
frequency of B cells (~10%) expressed T-bet compared to CD4+ T cells (~30%), CD8+ T cells 
(~65%), and NK cells (~100%), T-bet was consistently detected in B cells of all tested donors 
(Figures 1B and 1C). T-bet expression levels (median fluorescence intensity, or MFI) within the T-
bet+ B cell subset were comparable to T-bet+ T cells, while NK cells demonstrated the greatest T-
bet MFI (Figures 1B and 1D). Unlike T and NK cells, Eomes expression was not detected in B 
cells (Figures 1E and 1F). Monocytes and CD11c+ dendritic cells did not express either T-bet or 
Eomes (Figures 1B, 1C, 1E, 1F, and data not shown), suggesting Th1 transcription factors do not 
regulate human myeloid cells at rest.  
 T-bet expression in T cells is restricted specifically to memory subsets (100). In order to 
define T-bet+ B cell populations in human blood, we developed a panel to assess all major 
peripheral B cell subsets through expression of CD10, CD38, CD27, CD21, and immunoglobulin 
(Ig) D (Figure 2A). We found that significantly more memory B cells expressed T-bet compared to 
transitional B cells, naïve B cells, and plasmablasts (Figures 2B and 2C). As T-bet is known to 
regulate antibody class switching to IgG2a/c in mice (78, 110), we further assessed the 
relationship between T-bet and human memory B cell BCR isotypes (Figure 2D). T-bet was 
expressed at the highest frequency by IgG+ cells, specifically those expressing IgG1 or IgG3, 
which are critical for antiviral responses ((52); Figure 2E). However, T-bet expression could also 
be detected to a lesser degree in subsets of B cells expressing the other tested antibody isotypes 
(Figure 2E). 
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Figure 1: T-bet expression in peripheral blood lymphocytes and monocytes 
(A) Gating scheme depicting the identification of major blood immune subsets in a healthy 
individual; monocytes, CD3-CD14+CD19-; B cells, CD3-CD14-CD19+; CD4+ T cells, CD3+CD14-
CD19-CD4+CD8-; CD8+ T cells, CD3+CD14-CD19-CD4-CD8+; NK cells, CD3-CD14-CD19-CD4-
CD8-CD7+CD56+/CD16+. (B) Histogram depicting T-bet expression per subset from a 
representative individual; CD4+ T cells, blue; CD8+ T cells, grey; NK cells, black; B cells, red; 
monocytes, green. (C) Frequency of T-bet expression of each subset in an 8-donor cohort. (D) T-
bet MFI of T-bet+ cells per subset. (E) Histogram depicting Eomes expression of each subset 
from a representative individual. (F) Frequency of Eomes expression per subset.  
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Figure 2: T-bet expression in B cell subsets and by antibody isotype 
(A) Representative gating scheme for the identification of B cell subsets named in red from the 
peripheral blood of a healthy human donor. Trans., transitional, CD19+CD10+CD38midCD27-; PBs, 
plasmablasts, CD19+CD10-CD38highCD27high; naïve, CD19+CD10-CD38lowCD21+CD27-IgD+; total 
memory cells, CD19+CD10-CD38low excluding the naïve (CD21+CD27-) population. (B) 
Representative flow cytometry plots of T-bet expression in peripheral blood B cell subsets from a 
single donor. (C) T-bet expression frequency per subset in a 10-donor cohort. Bars on these and 
all following plots represent mean ± standard error. (D) Representative identification of memory B 
cell surface-expressed antibody (BCR) isotypes named in red. (E) T-bet expression frequency of 
memory B cells expressing different antibody isotypes. Statistical comparisons in C and E 
calculated using repeated measures one-way ANOVA with Tukey’s multiple comparisons test. ** 
denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001. 
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2.3.2 Identification of T-bethigh and T-betlow B cell subsets 
 
To further define the characteristics of T-bet+ memory B cells, we used CD21 and CD27 to 
delineate several previously described populations ((151); Figure 3A). The two CD21- subsets, 
activated memory (AM, CD21-CD27+) and tissue-like memory (TLM, CD21-CD27-) B cells, 
expressed T-bet at the highest frequencies (Figure 3B) and at significantly higher levels per cell 
(Figure 3C) compared to resting memory (RM, CD21+CD27+) cells, indicating a prominent role for 
T-bet in regulation of the peripheral CD21- memory B cell compartment. Interestingly, we 
identified a bimodal expression pattern of T-bet in AM and TLM subsets (Figure 3D); we therefore 
explored additional cell surface receptors to better demarcate CD21-T-bet+ B cells and found that 
this subset also highly expresses the inhibitory receptor CD85j (Figures 3E-G). The CD21-T-
bethighCD85jhigh population (hereafter referred to as T-bethighCD85jhigh cells) was comprised of 
approximately half the TLM population and nearly all of the AM population, whereas the 
remaining TLM cells represent the CD21-CD85jlow population (Figures 3H and 3I). In summary, 
we identified two populations of T-bet+ B cells: a RM subset expressing T-bet at low levels (T-
betlow cells) and a subset distinguished by a lack of CD21 expression and high levels of CD85j 
that represents the main T-bethigh B cell population in the peripheral blood of healthy human 
donors. 
 
2.3.3 T-bethighCD85jhigh B cells represent a transcriptionally and phenotypically distinct 
memory subset  
 
Seeking to better define this novel subset, we next investigated the transcriptional environment of 
T-bethigh B cells, using the CD85jhigh phenotype as a surrogate marker for Fluidigm Biomark 
quantitative RNA analysis. Figure 4A depicts transcript expression levels of 91 selected target 
genes, including transcription factors, activation and inhibitory receptors, trafficking receptors, cell 
survival/death proteins, and other B cell-relevant genes within sorted B cell subsets from four  
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Figure 3: T-bet expression in peripheral blood memory B cell subsets 
(A) CD21/CD27-based gating scheme of total CD38lowCD10- B cells from a representative donor; 
activating memory, AM, CD27+CD21-; resting memory, RM, CD27+CD21+; tissue-like memory, 
TLM, CD27-CD21-. (B) T-bet expression frequency of CD21/CD27-derived B cell subsets. (C) T-
bet median fluorescence intensity (MFI) of T-bet+ cells from each B cell subset. (D) AM (blue) and 
TLM (black) T-bet expression histogram from a representative donor. (E) Gating of CD21-
CD85jhigh and CD21-CD85jlow B cell subsets from a representative donor’s total CD38lowCD10- B 
cells. (F) T-bet expression histogram of CD85j-gated B cell subsets from donor depicted in E. (G) 
T-bet expression frequency of CD85j-gated B cell subsets in 10-donor cohort. (H) Flow cytometry 
plots depicting the gating of AM and TLM into CD85jhigh and CD85jlow populations. Total B cells 
are depicted in black contour plot; TLM/AM subsets are depicted in blue dot plot. (I) Frequency of 
AM and TLM subsets demonstrating the CD85j high phenotype (n=10 donors). Statistical 
comparisons in B and C calculated using repeated measures one-way ANOVA with Tukey’s 
multiple comparisons test. Statistical comparison in G calculated using paired t-test. *** denotes a 
P value < 0.001. 
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healthy donors. Unbiased clustering analysis of gene expression data demonstrated consistent 
clustering of B cell subsets between donors, indicating our chosen panel clearly differentiates 
peripheral B cell populations (Figure 4A). T-bethighCD85jhigh cells’ transcriptional signature 
included highest expression of the antibody class switching and somatic hypermutation enzyme 
AICDA, the glycosylation enzyme B4GALT3, transcription factors IKZF1 (Ikaros) and SOX5, the 
inhibitory receptor SIGLEC6, and, importantly, TBX21 (T-bet) (Figure 4A). CD85j high cells 
shared high expression of CCR6, FCRL3, FCRL4, NFIL3, PBX4, and TNF with RM cells, FCRL5 
and TOX2 with plasmablasts, and BATF, CASP3, CD27, FAS, FUCA2, FUT8, and POU2AF1 
with both populations (Figure 4A). 
 To interrogate transcriptional similarity between T-bethighCD85jhigh cells and the other 
sorted B cell subsets in an unbiased way, we performed t-distributed stochastic neighbor 
embedding (tSNE) analysis of the transcript expression results (Figure 4B). T-bethighCD85jhigh 
cells were transcriptionally dissimilar to antigen-inexperienced B cells and clustered near to, but 
distinct from, resting memory B cells and plasmablasts, further suggesting this is an antigen-
experienced population. Interestingly, CD85j low B cells, the CD21-T-bet- counterpart of our cells 
of interest, were more similar to the antigen-inexperienced subsets (naïve, transitional; Figure 
4B), suggesting these are relatively unrelated to T-bethighCD85jhigh cells and confirming the 
previously described population heterogeneity within the TLM phenotype (CD21-CD27-; (171)). 
 We further assessed phenotypes of T-bethighCD85jhigh cells at the protein level and found 
this subset also highly expressed several homing receptors, activation markers, additional 
inhibitory receptors (Figure 4C), and demonstrated a diverse repertoire of antibody isotypes 
(Figure 4D). Interestingly, T-bethighCD85jhigh cells highly expressed the transcription factor 
irrespective of surface Ig isotype expression (Figure 4E), suggesting additional Ig isotype-
independent roles for T-bet in this population. Taken together, comparative transcriptional and 
phenotypic studies identify T-bethighCD85jhigh cells as a highly activated, antigen-experienced 
population characterized by distinctive homing receptor and transcriptional profiles.   
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Figure 4: Transcriptional and phenotypic analyses of T-bethighCD85jhigh cells and other B 
cell subsets 
(A) Heat map depicting relative RNA transcript expression levels for 91 targets (one per row) in 
HIV-negative donors (n=4). Each column represents a specific B cell subset (colored bars above 
and below heat map) sorted from one donor. (B) tSNE analysis of transcriptional relationships 
between sorted B cell subsets from four healthy donors. Each color represents a sorted B cell 
subset and clusters are highlighted with the corresponding color. (C) Expression frequency of 
homing receptors (CD11c, CXCR3), activation markers (CD69, CD71, CD86, CD95), and 
inhibitory receptors (PD-1, FcRL4/5) by CD38lowCD10- B cell subsets. (D) Frequency of antibody 
isotypes expressed by T-bethighCD85jhigh cells (n=10). (E) T-bet expression frequency of T-
bethighCD85jhigh cells separated by Ig isotype (n=10). Statistical comparisons in C and E 
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calculated using repeated measures one-way ANOVA with Tukey’s multiple comparisons test. No 
statistical differences were observed between isotypes in E. Statistical comparison in I calculated 
using paired t-test. * denotes a P value 0.05 > P ≥ 0.01. ** denotes a P value 0.01 > P ≥ 0.001. 
*** denotes a P value < 0.001. 
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2.3.4 Divergent circulatory patterns between T-bethigh and T-betlow B cells  
 
We hypothesized that the differing phenotypes of T-bethigh and T-betlow B cells would impact their 
migratory capacity. To understand the circulatory potential of these subsets, we compared the 
composition of B cell compartments in peripheral blood (PBMC) to the thoracic duct (TD), the 
body’s largest lymphatic vessel that collects lymph draining from both lymphoid and non-lymphoid 
tissues and empties into the blood (90). We isolated mononuclear cells from paired peripheral 
blood and thoracic duct fluid (chyle) samples obtained from adults undergoing interventional 
surgery (see Methods). Compared to PBMC, TD generally lacked myeloid cells and was 
comprised mainly of T cells, B cells, and a small number of NK cells (data not shown). We 
assessed the main B cell subset phenotypes found in healthy human blood (Figure 2A) and 
identified the presence of transitional, naïve, memory, and plasmablast populations in TD of all 
donors (Figure 5A). Transitional B cell and plasmablast frequencies were similar between PBMC 
and TD compartments (data not shown), while memory B cells were underrepresented in TD 
compared to PBMC and naïve cells were more frequent in TD (Figure 5B). Overall, the B cell 
compartment within these two anatomical sites was similar.  
 We next investigated T-bet expression by TD B cells and consistently identified 
diminished frequencies of total T-bet+ memory B cells in TD compared to PBMC (Figures 5C and 
10D), suggesting some T-bet+ B cell subsets may not migrate through the thoracic duct. To 
understand this phenomenon, we examined T-bethigh cells (CD21-T-bethighCD85jhigh phenotype; 
see Figures 3E and 3F) and found that this subset was virtually absent from the TD B cell 
compartment, despite detectable T-bethigh cell frequencies in PBMC of all matched donors 
(Figures 5E and 5F). Conversely, T-betlow cells, which could be readily identified within the CD21+ 
population by CXCR3 expression (Figures 5G and 5H), were present at comparable frequencies 
in both PBMC and TD (Figure 5I). These findings suggest differential circulatory capacities of T-
bethigh and T-betlow cells: T-betlowCXCR3+ cells migrate through the thoracic duct and are able to 
re-circulate back into blood, while T-bethigh cells rarely enter into lymph.  
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Figure 5: B cell subset distribution and T-bet expression in paired peripheral blood and 
thoracic duct samples 
(A) Gating scheme depicting identification of major B cell subsets as defined in Figure 2A from a 
representative donor’s peripheral blood (PBMC) and thoracic duct fluid (TD). (B) Frequency of 
naïve (black) and total memory (blue) B cells in 8-donor cohort. (C) Representative flow 
cytometry plots of T-bet expression in total memory B cells from a representative donor’s PBMC 
and TD. (D) T-bet expression frequency in total memory B cells from PBMC and TD in 8-donor 
cohort. (E) Identification of T-bethighCD85jhigh subset within total B cells from a representative 
donor’s PBMC and TD. (F) Frequency of T-bethighCD85jhigh subset within total B cells in 8-donor 
cohort. (G) Identification of CXCR3+ (blue) and CXCR3- (red) subsets within RM (CD21+CD27+) 
population of PBMC and TD. (H) T-bet expression histograms of CXCR3+ (blue) and CXCR3- 
(red) subsets from G in PBMC and TD. (I) Frequency of T-betlowCXCR3+ subset within total B 
cells in 8-donor cohort. Statistical comparisons in B, D, F, and I calculated using paired t-test. ** 
denotes a P value 0.01 > P ≥ 0.001.  
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2.3.5 Human spleen harbors a large T-bet-expressing B cell population 
 
Having identified diverse circulatory patterns, we next investigated the tissue distribution of T-bet+ 
B cell subsets. We assessed T-bet expression in B cells obtained from different lymphoid tissues, 
including iliac lymph nodes (iLN), mesenteric lymph nodes (mLN), tonsils, and spleens that were 
acquired following surgery (Figure 6A). Iliac lymph node, mesenteric lymph node, and tonsil B 
cells expressed T-bet at a similar, albeit reduced, frequency compared to PBMC B cells (Figures 
6A and 6B); however, MFI of the T-bet+ population in each case was significantly lower than that 
of PBMC B cells (Figure 6C). To determine the types of lymphoid tissue B cells expressing T-bet, 
we examined major lymph node B cell subsets and identified six donor samples for analysis (two 
mLN, four tonsil) in which each of the lymphoid populations was sufficiently represented (Figure 
6D). T-bet was not characteristically expressed by any specific lymphoid tissue B cell subset, and 
low T-bet MFI made detection difficult (Figure 6E); however, germinal center B cells (GC; 
CD38midBcl-6+CD10+Ki67+CD21+) and CD27+ memory B cells exhibited increased T-bet MFI 
compared to naïve and germinal center-like (GC-like; CD38midBcl-6-CD10+Ki67+CD21-) B cells 
(Figures 6E and 6F). Notably, T-bet expression in lymphoid tissues did not associate with 
diminished CD21 expression as it does in PBMC (Figure 3). In summary, T-bet is expressed only 
at low levels (frequency and MFI) in iLN, mLN, and tonsil in the absence of an apparent, active 
immune response, specifically in the GC and CD27+ memory subsets. 
 The spleen is a physiologically distinct lymphoid organ comprised of a white pulp region 
bearing similarities to lymph nodes and a red pulp region in which macrophages directly sample 
the blood for antigens (91). The spleen’s B cell compartment also differed significantly from the 
other assessed lymphoid organs, as spleen samples contained a large memory B cell population 
but few GC or GC-like B cells (data not shown). Interestingly, splenic B cells expressed T-bet at a 
significantly higher frequency and MFI than PBMC, iLN, mLN, and tonsil B cells (Figures 6A, 6B, 
and 6C), suggesting the spleen may characteristically harbor a large T-bet+ B cell population. 
These T-bet+ B cells were comprised of two distinct subsets: a small CD21-T-bethighCD85jhigh B  
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Figure 6: T-bet expression in iliac lymph nodes, mesenteric lymph nodes, tonsil, and 
spleen 
(A) Flow plots depicting representative T-bet expression in total B cells from various unpaired 
lymphoid tissues; peripheral blood, PBMC; iliac lymph node, iLN; mesenteric lymph node, mLN. 
(B) Frequency of T-bet expression per lymphoid tissue B cell population; 6 PBMC, 6 iLN, 6 mLN, 
4 tonsil, 6 spleen samples. (C) T-bet MFI of the T-bet+ B cells from each lymphoid tissue. (D) 
Identification of lymph node subsets in a representative mLN, with subsets named in red; 
germinal center B cells, GC, CD38midBcl-6+CD10+Ki67+CD21+; germinal center-like B cells, GC-
like, CD38midBcl-6-CD10+Ki67+CD21-; plasmablasts, PB, CD38high; CD27+ memory, 
CD38lowCD27+; naïve, CD38lowCD27-CD21+. (E) T-bet histogram of lymph node subsets from a 
representative mLN; naïve, grey; GC-like, blue; GC, red; CD27+ memory, black. (F) T-bet MFI of 
lymph node subsets in 6-donor cohort (2 mLN, 4 tonsil). (G) Identification of CD21+T-bet+ and 
CD21-T-bet+ subsets in PBMC and spleen of two representative donors. (H) Identification of 
CD21+ spenic subsets named in red from a representative donor. (I) T-bet expression frequency 
of splenic CD21+ subsets in 6 donor cohort split into two groups: donors with high (>40%; blue) 
and low (<40%; black) total frequencies of T-bet expression in the spleen in (see Figure 6B). 
Statistical comparisons in B, C, and F calculated using one-way ANOVA with Tukey’s multiple 
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comparisons test. * denotes a P value 0.05 > P ≥ 0.01; ** denotes a P value 0.01 > P ≥ 0.001. *** 
denotes a P value < 0.001. 
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cell population that phenotypically resembled its PBMC counterpart (Figure 6G), and a large 
CD21+T-bet+ B cell population that dwarfed the PBMC CD21+T-bet+ subset in size and accounted 
for the majority of T-bet+ B cells in spleen (Figure 6G).  
 To better define splenic CD21+T-bet+ B cells, we investigated the association between T-
bet and diverse phenotypes within the CD21+ population (Figure 6H). T-bet was detected in all 
CD21+ memory subsets examined, including isotype switched (IgM-), unswitched (IgM+), CD27+, 
and CD27- populations, with CD27+IgM- memory B cells expressing T-bet at the highest 
frequency (Figure 6I). We also observed T-bet expression by phenotypically naïve B cells 
(CD21+CD27-IgD+), suggesting T-bet induction may precede the development of a memory B cell 
phenotype in this tissue (Figure 6I). Interestingly, individuals with particularly high T-bet+ splenic B 
cell frequencies (>40% T-bet+; Figure 6B) did not exhibit expansion of a particular T-bet-
expressing subset; instead, they maintained a phenotypically diverse splenic CD21+T-bet+ B cell 
pool with elevated T-bet expression frequencies across all subsets (Figure 6I). Together, these 
findings suggest human spleen represents a reservoir for members of the T-bet+ B cell 
population. 
 
2.3.6 T-bet+ B cells are induced during acute viral infections 
	  
T-bet+ B cells have previously been shown to expand during acute LCMV and ghv68 infections in 
mice (117, 118); we therefore asked whether human T-bet+ B cells might similarly be induced 
during human acute viral infections. To assess this, we examined B cell responses in yellow fever 
(YFV) and vaccinia (VV) virus vaccinated human subjects. These replicating live virus vaccines 
are thought to elicit durable protection via antibody-mediated mechanisms (4, 172-174), 
suggesting a critical role for B cells in this process. We analyzed T-bet expression within total 
memory B cells collected from the peripheral blood of vaccinated individuals on the day of 
vaccination, at weekly acute time points, and at a final time point ranging from 2 to 8 months post-
vaccination (Table 1). We identified the emergence of a T-bet+ population as early as two weeks  
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Vaccinia 
Donor 
ID 
Week 
0 
Week 
1 
Week 
2 
Week 
3 
Week 
4 
Week 
25+ 
  12 Pre 7 14 21 28 180 
  13 Pre 7 17 21 28 184 
  501 Pre 7 15 22 29 183 
  502 Pre 7 14 23 28 183 
  503 Pre 7 14 21 28 181 
  507 Pre 7 14 21 29 195 
  548 Pre 7 14 21 28 271 
Yellow 
Fever 
Donor 
ID 
Week 
0 
Week 
1 
Week 
2 
Week 
3 
Week 
4 Week 8+ 
  4 Pre 8 15 20 28 184 
  12 Pre n/a 14 22 30 203 
  558 1 n/a 15 22 29 218 
  559 1 8 15 22 32 120 
  565 1 9 16 23 30 60 
 
Table 1: Yellow fever virus and vaccinia virus vaccine recipients. Blood sample timing for 
n=7 vaccinia virus vaccine recipients and n=5 yellow fever vaccine recipients are depicted in 
Table 1. Each row represents one donor with longitudinal samples collected at each day post 
vaccination. Columns show binning of sampling into weeks post vaccination. 
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post-YFV and VV vaccinations, which expanded and remained detectable in peripheral blood 
through week four post-vaccination (Figures 7A and 7B). The frequency of total T-bet+ B cells 
peaked around week four in the majority of individuals receiving either YFV (Figure 7C) or VV 
(Figure 7D) vaccination, suggesting that both vaccines stimulated a T-bet+ B cell response. The 
T-bethighCD85jhigh B cell frequency also peaked at week four in YFV-vaccinated individuals (Figure 
7E), and expansion was preceded by expression of the activation marker Ki67 in this population 
at week two post vaccination (Figure 7F). While T-bethighCD85jhigh cell expansion was not 
detected in all donors during VV vaccination (Figure 7G), T-bet MFI in T-bethighCD85jhigh cells was 
dynamic and peaked between weeks three and four during both YFV and VV responses (Figures 
7H and 7I, blue lines). These responses were not limited to a single surface Ig isotype, as T-bet 
expression increased in both IgM+ and class-switched T-bethighCD85jhigh cells (Figures 7J and 
7K). Resting memory B cells (RM), which normally express low levels of T-bet (Figure 3B), 
displayed increased T-bet expression frequencies in several VV vaccine recipients (Figure 7M) 
but only in one YFV vaccine recipient (Figure 7L). This RM T-bet response involved only a small 
subset of cells, as RM population size did not increase (data not shown) and T-bet MFI in the 
total population remained static during both vaccinations (Figures 7H and 7I, black lines). 
Interestingly, T-bet levels in plasmablasts also increased following each vaccination (Figures 7N 
and 7O). Together, these findings indicate that human live viral vaccinations stimulate an acute T-
bet+ B cell response and that the T-bethighCD85jhigh population may function as an early-responder 
during acute viral infections. 
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Figure 7: Longitudinal T-bet+ B cell dynamics in yellow fever virus-vaccinated or vaccinia 
virus-vaccinated individuals 
Longitudinal T-bet expression in memory B cells of (A) a yellow fever (YFV) vaccinee and (B) a 
vaccinia (VV) vaccinee. Time of blood sampling post-vaccination is depicted. (C) T-bet 
expression frequency in total memory B cells of YFV vaccinees (n=5 for all YFV plots except F). 
Donor samples were binned to organize approximate weekly time points. (D) T-bet expression 
frequency of memory B cells in VV vaccinees (n=7 for all VV plots). (E) T-bethighCD85jhigh cell 
frequency of total memory B cells in YFV vaccinees. (F) Ki67 expression frequency of T-
bethighCD85jhigh cells in YFV vaccines (n=4). (G) T-bethighCD85jhigh cell frequency of total memory 
B cells in VV vaccinees. (H) T-bet MFI of T-bethighCD85jhigh cells (blue) and resting memory (RM) 
cells (black) in YFV vaccinees. No statistical differences were observed between RM time points. 
(I) T-bet MFI of T-bethighCD85jhigh cells (blue) and resting memory (RM) cells (black) from VV 
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vaccinnees. No statistical differences were observed between RM time points. T-bet MFI of T-
bethighCD85jhigh cells separated by IgM expression is depicted in (J) for YFV and (K) for VV; IgM+, 
black; IgM- grey. Frequencies of RM cells expressing T-bet during YFV (L) and VV (M) responses 
are shown. No significant differences were observed in L between time points. (N) T-bet MFI of 
plasmablasts following YFV vaccination. (O) T-bet MFI of plasmablasts following VV vaccination. 
Statistical comparisons in C, D, E, F, G, H, I, L, M, N and O calculated using repeated measures 
one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. ** 
denotes a P value 0.01 > P ≥ 0.001.  
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2.4 Discussion 
 
The nature of the acute B cell response to human viruses remains poorly defined. To address this 
issue, we assessed the phenotype and dynamics of B cells expressing T-bet, a known regulator 
of Th1-type immunity across cell lineages, at rest and during acute human viral infections. We 
identified T-bet+ B cells in the peripheral blood memory compartment of healthy individuals and 
found an enrichment of antiviral antibody isotypes in this population. We further characterized T-
betlow and T-bethigh B cell subsets, the latter of which represents a distinct antigen-experienced 
population with an activated phenotype. These subsets further displayed disparate tissue 
localization profiles, as T-betlow B cells were found in peripheral blood, thoracic duct fluid, and 
various lymphoid tissues, while T-bethigh B cells were restricted to the blood and spleen. B cell T-
bet expression frequencies transiently increased in the blood in response to acute YFV and VV 
infections, a phenomenon attributable to T-bet induction across multiple B cell subsets and the 
specific activation and expansion of T-bethighCD85jhigh cells.  
T-bet is considered to function as a master regulator of Th1-type immunity (100), and T-
bet is known to promote antiviral B cell responses by driving IgG2a/c class-switching in mice (78, 
110, 117, 118). Our findings suggest T-bet similarly regulates human B cells during acute Th1 
immune responses, as we clearly demonstrate viral infection-induced T-bet expression in multiple 
human B cell subsets. Our results further suggest antibody isotype diversification as a key effect 
of this T-bet induction, as T-bet associates with the IgG1 and IgG3 isotypes in healthy individuals. 
However, we also observed activation of the T-bet+IgM+ population in response to acute YFV and 
VV infections; further experiments are necessary to determine if these IgM+ memory cells are 
particularly prone to IgG1 or IgG3 isotype switching, but this observation suggests additional 
antibody isotype-independent roles for T-bet in human B cells. T-bet may influence additional 
antibodies properties, as T-bethighCD85jhigh cells demonstrate elevated RNA transcript levels of 
B4GALT3, a galactosyltransferase that may alter antibody glycosylation (36), and AICDA, the 
enzyme critical for somatic hypermutation that leads to improved antibody affinity (37). T-bet may 
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also influence antibody-independent functions and properties: similar to mice (79, 117), T-bet 
likely regulates the expression of homing receptors CXCR3 and CD11c in human B cells, 
potentially granting specific tissue and inflammation homing properties to T-bet+ cells. Murine 
studies further suggest T-bet+ B cells in the spleen efficiently present antigen (63) and can be 
stimulated to produce the cytokine IFNγ (65).  
Our study identified a heterogeneous T-bet-expressing B cell population in human blood 
comprised of two main subsets: T-bethighCD85jhigh cells (CD21-T-bethighCD85jhigh) and T-bet-
expressing RM cells (CD21+CD27+T-betlow). T-bethighCD85jhigh cells expand in response to acute 
human viral infections (YFV and VV vaccinations) and closely resemble age-associated B cells, a 
T-bet+ population in mice that accumulates with age, produces pathogenic autoantibodies, and is 
critical for murine antiviral responses (114, 115, 117, 118). In contrast to T-bethighCD85jhigh cells, 
we did not observe significant expansion or activation of T-betlow cells in most individuals 
following YFV or VV vaccination, suggesting this subset does not play an active role during acute 
antiviral B cell responses. While the origin and functions of T-betlow cells remain unclear, they 
may represent quiescent descendants of T-bethighCD85jhigh cells that maintain long-lived antiviral 
memory, as acutely-activated virus-specific B cell clones have been shown to seed the RM 
population following resolution of acute infection (159). 
We further identified differential circulatory abilities and tissue distributions of T-bethigh 
and T-betlow cells. The T-betlow population was found in all assessed tissues, suggesting 
peripheral blood T-betlow cells can enter into lymphoid organs, exit via the efferent lymph, and 
travel to other lymphoid tissues or back into the blood via the thoracic duct. It is unclear whether 
these cells remain in lymphoid tissue for extended periods of time or pass through transiently. 
Conversely, we identified T-bethigh cells in peripheral blood and the spleen but could not detect 
them in lymph nodes, tonsil, or thoracic duct fluid, suggesting T-bethigh cells do not traffic into 
lymph nodes and do not egress from tissues in the absence of an immune response. The 
relationship between splenic CD21+T-bet+ cells and the peripheral T-bethigh and T-betlow subsets is 
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unclear, but the sheer size of the splenic CD21+T-bet+ population suggests portions of these cells 
are spleen-resident.  
 In summary, our study identifies T-bethigh B cells as a novel viral infection-responsive 
subset and suggests T-bet as an important mechanism regulating humoral antiviral immunity in 
humans. T-bethigh B cells’ rapid expansion during acute viral infections is reminiscent of effector T 
cells and suggests they participate in the immune response by generating IgG1 and IgG3 isotype 
antibodies and homing to sites of inflammation. In combination with T-bethigh B cells’ 
responsiveness to viral infection, the previously reported outgrowth of T-bet-expressing B cells 
during inflammatory conditions (120, 121, 162, 165, 166) suggests this population may be broadly 
sensitive to inflammatory signals. Future studies should assess the direct contribution of T-bethigh 
B cells to antigen-specific responses and investigate relationships between disparate T-bet+ 
tissue B cell subsets to fully define the human T-bet+ B cell compartment’s immunological niche. 
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CHAPTER 3 
	  
T-BET-EXPRESSING B LYMPHOCYTES ARE INDUCED BY HIV INFECTION AND 
DOMINATE THE GP140-SPECIFIC B CELL RESPONSE 
 
3.1 Summary 
 
Current HIV vaccine efforts seek to induce protective antibodies, but the development and 
regulation of the B cell response to HIV remain poorly understood. Here, we assessed the role of 
T-bet-expressing B cells, a population critical for murine antiviral responses, during HIV infection. 
T-bet+ B cells expanded during early acute HIV infection, were maintained at excessive levels in 
chronic viremic infection, and associated with increased serum and cell-associated IgG1 and 
IgG3 expression. Viral control was associated with contracting frequencies of T-bethigh B cells, but 
T-betlow B cells remained expanded in many aviremic donors. siRNA knockdown studies further 
suggested a role for T-bet in the regulation of activation-induced cytidine deaminase RNA 
expression. The HIV gp140-specific B cell response was dominated by T-bet-expressing memory 
B cells, and we observed a concomitant biasing of gp140-specific serum immunoglobulin to the 
IgG1 isotype. These findings suggest sustained T-bet induction by HIV infection alters the isotype 
landscape of the B cell compartment and drives expansion and maintenance of a large T-bet+ B 
cell population that coordinates the HIV Env-specific humoral response. 
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3.2 Introduction 
 
The HIV pandemic persists as one of the most significant global health problems (131). While 
antiretroviral therapy has greatly improved mortality rates, a preventative vaccine remains 
necessary to curtail the spread of HIV (175). Efforts have shifted to rational-based vaccine 
design, requiring an in-depth analysis of immune responses to identify and stimulate protective 
immunological correlates (144). Recent isolation and characterization of many naturally occurring 
HIV-specific broadly neutralizing antibodies demonstrates the capacity of humans to generate a 
potentially protective humoral response (176), but the B cells and mechanisms regulating 
humoral immunity to HIV remain poorly characterized. An improved understanding of the B cell 
response will identify interventional targets and inform rational vaccine design for HIV and other 
viruses for which broadly effective vaccines do not exist.  
HIV infection is characterized by excessive viral replication and inflammation that induce 
a strong virus-specific humoral response and promote polyclonal B cell stimulation (54, 147). This 
B cell hyperactivation likely contributes to previously described B cell subset alterations in 
chronically infected individuals (147). The memory B cell compartment is particularly impacted by 
HIV, with decreased resting memory B cell numbers and an expansion of activated and atypical 
memory B cells that lack expression of the complement receptor CD21 (150, 151). It was 
previously demonstrated that HIV-specific responses are over-represented in CD21- memory B 
cells in viremic individuals (155), but the factors regulating HIV-specific B cells are unclear.  
B cells expressing the transcription factor T-bet, a broad regulator of Th1-type immune 
responses, are critical for controlling murine chronic viral infections (117, 118). We recently 
identified T-bet-expressing B cells in human peripheral blood that are enriched for IgG1 and IgG3, 
two antibody isotypes that efficiently mediate antiviral effector functions (Chapter 2). T-bethigh 
cells, a subset of this population, are highly activated and transiently expand in response to 
vaccination with diverse replicating viruses. These properties suggest T-bet+ B cells participate in 
human antiviral responses, but their role during HIV infection is unknown.  
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In this study we examine HIV-induced T-bet expression in B cells, the consequences of 
this induction, and the involvement of T-bet+ B cells in the HIV immune response. We identified 
rapid activation and expansion of T-bet+ B cells and increased T-bet expression levels in 
plasmablasts during early acute HIV infection. Following the resolution of acute infection, the T-
bet+ memory B cell population was maintained at a high frequency into chronic HIV infection and 
correlated with increased expression and secretion of IgG1 and IgG3 antibodies. This T-bet+ B 
cell population maintains the anti-gp140 B cell response and, via the expression of T-bet, likely 
biases gp140-specific antibodies to the IgG1 isotype. Our data identify T-bet+ B cells as 
responders during both acute and chronic HIV infection and suggest this population orchestrates 
the humoral immune response to HIV.  
 
 
3.3 Results 
 
3.3.1 Acute HIV infection induces T-bet+ B cell population expansion 
	  
In our previous study (Chapter 2) we assessed B cell dynamics during YFV and VV vaccinations, 
which represent relatively controlled, low inflammation infections. We therefore investigated 
whether T-bet+ B cells similarly expand during acute HIV infection, which is characterized by 
excessive inflammation and immune pathology. To assess this, we obtained longitudinal 
peripheral blood mononuclear cell samples from high-risk HIV seronegative individuals who 
subsequently became infected with HIV from the U.S. Military HIV Research Program RV217 
early capture HIV cohort (177). We analyzed T-bet expression in total memory B cells (Figure 2A) 
from pre-infection, early acute, and early chronic infection time points (Table 2). During early 
acute infection (days 1-21 after first positive HIV RNA test), six out of seven individuals 
demonstrated a rapid increase in the frequency of T-bet-expressing memory B cells, supporting 
the role of these cells as part of an early antiviral response (Figure 8A and 8B). Similar to YFV  
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Figure 8: Longitudinal T-bet+ B cell dynamics in acutely HIV-infected individuals 
(A) T-bet expression in memory B cells of an acutely HIV-infected individual before infection and 
shortly after peak of viremia. (B) Memory B cell T-bet expression frequency from 7-donor cohort 
of acutely HIV-infected individuals at pre-infection, acute, and chronic infection time points. (C) T-
bet MFI of plasmablasts at pre-infection, acute, and chronic infection time points. Note that 
intracellular T-bet staining for these samples was performed using BD Cytofix/Cytoperm Kit (Cat. 
# 554722). Statistical comparisons in B and C calculated using repeated measures one-way 
ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. ** denotes a 
P value 0.01 > P ≥ 0.001.  
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Donor ID 
Day relative 
to first pos. 
test 
VL 
(copies/ml) 
CD4 count 
(cells/ul) 
10374 -194 n/a n/a 
  21 10965 775 
  407 17783 446 
30507 -289 n/a n/a 
  17 1122 1574 
  413 7585 n/a 
40067 -467 n/a n/a 
  1 229087 565 
  403 23988 425 
40134 -69 n/a n/a 
  2 2454709 435 
  433 13804 n/a 
40250 -173 n/a n/a 
  14 4677351 522 
  420 16596 461 
40283 -478 n/a n/a 
  1 398107 376 
  425 50199 n/a 
40353 -41 n/a n/a 
  14 162181 574 
  415 3388 448 
 
Table 2: RV217 Early Capture HIV cohort. Longitudinal samples were obtained at pre-infection, 
acute, and chronic infection time points for n=7 donors, with the collection date listed as day 
relative to first HIV-positive RNA test. Viral load and CD4 counts are listed where available. 
Individuals were therapy-naïve at the time of sampling. 
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and VV vaccinations (Chapter 2), we also observed increased T-bet MFI in plasmablasts at this 
acute time point (Figure 8C). These six individuals remained viremic into early chronic infection 
and concomitantly maintained elevated T-bet levels, suggesting a relationship between continued 
viral replication and maintenance of this expanded population (Figures 8B and 8C). 
 
3.3.2 Chronic HIV infection maintains an expanded T-bet+ B cell population 
 
Having observed the rapid expansion and sustained expression of T-bet+ B cells in acute to early 
chronic HIV infection, we next examined T-bet expression in memory B cells from chronically 
infected HIV+ cohorts with different viral loads: viremic HIV progressors (progressors; VL>10,000 
copies/ml), viremic controllers (VC; VL 41-1800 copies/ml), elite controllers (EC; VL <40 
copies/ml), aviremic individuals on antiretroviral therapy (ART; VL<40 copies/ml), and HIV-
negative controls (Tables 3 and 4). We identified a significant expansion of T-bet+ memory B cells 
in HIV-infected progressors and viremic controllers compared to healthy controls (Figure 9A and 
9B). In progressors, individuals with the highest viremia, this expansion was comprised almost 
entirely of T-bethighCD85jhigh B cells (Figure 9C) and coincided with higher expression levels (MFI) 
of T-bet (Figure 9D). Absence of detectable viremia in EC and ART was associated with 
decreased T-bet+ B cell population size in many donors compared to viremic individuals (Figure 
9B), which could be explained in part by diminished T-bethighCD85jhigh cell expansion in these 
cohorts (Figure 9E). We also observed a trend toward elevated T-bet expression frequencies in 
RM B cells in all HIV+ cohorts (Figure 9F); however, similar to our findings in HIV-negative donors 
(Chapter 2, Figure 3C), RM cell T-bet expression levels (MFI) remained low (data not shown). 
Lastly, we observed increased T-bet MFI in plasmablasts of progressors and viremic controllers 
(Figure 9G), suggesting together with our acute infection findings that viral replication also 
promotes T-bet expression in plasmablasts. Together, our data indicate chronic HIV viremia 
drives T-bet expression in both memory B cells and plasmablasts and maintains the expansion of 
the T-bethighCD85jhigh subset. 
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Donor ID Group VL CD4 ct. 
110029 ART Undetectable 800 
110564 ART Undetectable 1091 
110595 ART Undetectable 702 
110600 ART Undetectable 828 
110657 ART Undetectable 1188 
110869 ART Undetectable 679 
110870 ART Undetectable 693 
110887 ART Undetectable 689 
111031 ART Undetectable 338 
111096 ART Undetectable 686 
110015 ART Undetectable 698 
110029 ART Undetectable 624 
110043 ART Undetectable 564 
110054 ART Undetectable 644 
110163 ART Undetectable 640 
110206 ART Undetectable 423 
110285 ART Undetectable 481 
110313 ART Undetectable 804 
110334 ART Undetectable 431 
110348 ART Undetectable 1438 
110351 ART Undetectable 382 
110399 Prog. 141958 70 
110670 Prog. 198018 248 
110939 Prog. 97259 250 
110967 Prog. 224078 8 
111005 Prog. 41679 221 
111031 Prog. 500000 90 
111081 Prog. 280428 222 
111089 Prog. 339292 377 
111112 Prog. 466000 5 
111154 Prog. 205176 8 
110187 Prog. 14573 393 
110245 Prog. 10210 216 
110360 Prog. 25320 349 
110554 Prog. 41600 777 
110622 Prog. 57465 471 
110673 Prog. 28000 387 
110763 Prog. 25876 270 
110979 Prog. *Undetectable 1323 
111056 Prog. 145654 494 
111083 Prog. 17284 323 
111117 Prog. 33940 364 
130236 Prog. 28888  632  
130636 Prog. 35160  323 
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130716 Prog. 99562 19 
 
Table 3: University of Pennsylvania Center for AIDS Research donor samples. Viral loads 
and CD4 counts for chronically infected HIV+ cohorts, including antiretroviral therapy (ART)-
treated and ART-naïve, viremic individuals (Progressors), are depicted. The individual marked 
with * had undetectable viremia at the time of collection but had a viral load of 18,083 at the 
subsequent clinic visit 20 months later.  
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Donor ID 
Grou
p VL 
CD4 
ct. 
1161 VC 360 1185 
1176 EC <40 757 
1203 EC <40 890 
1204 EC <40 1032 
1215 VC 1183 1747 
1247 VC 1102 591 
1277 VC 76.3 1074 
1367 EC <40 566 
1446 VC 305 1086 
1448 VC 1400 485 
1508 VC 201 427 
1526 EC <40 531 
1527 EC <40 1085 
1541 VC 1589 1174 
1545 VC 182 625 
1555 EC <40 613 
1581 EC <40 1227 
1637 VC 676 909 
3604 EC <40 912 
4014 EC <40 982 
 
Table 4: University of California San Francisco SCOPE cohort. Viral loads and CD4 counts 
for viremic controllers (VL 41-1800 copies/ml) and elite controllers (VL <40 copies/ml) are 
depicted. All individuals were therapy-naïve at time of sampling. 
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 As our data implicate T-bethighCD85jhigh cells as participants in antiviral responses, and 
members of this population have been described as exhausted during chronic HIV infection (151), 
we next asked whether chronic HIV infection might selectively induce transcriptional changes in 
T-bethighCD85jhigh cells and therefore potentially impact their functionality. We compared RNA 
transcript levels of our 91-member panel (Chapter 2, Figure 4A) in T-bethighCD85jhigh cells 
between HIV-negative individuals (n=4) and progressors (n=5) and found that T-bethighCD85jhigh 
cells appear largely similar regardless of HIV infection status (Figure 9H). These findings suggest 
that, while viremic HIV infection greatly expands and maintains the T-bethighCD85jhigh population, 
it does not overtly alter the transcriptional environment of these cells during the course of 
infection. 
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Figure 9: T-bet expression in B cells and RNA transcript levels in T-bethighCD85jhigh cells 
during HIV infection.  
(A) T-bet expression in memory B cells of a representative HIV-negative donor and an HIV+ 
chronic progressor (progressor). (B) T-bet expression frequency of memory B cells in HIV-
negative, progressor, HIV+ viremic controller (VC), HIV+ elite controller (EC), and HIV+ 
antiretroviral therapy-treated donors (ART); n=10 donors per group. (C) Phenotype of T-bet+ B 
cell population from each cohort in B. Bars represent standard error. (D) T-bet MFI of total T-bet+ 
cells from each cohort. (E) Correlation of total T-bet expression and T-bethighCD85jhigh cell 
frequencies of memory B cells. Four HIV+ cohorts are represented by different colors: 
Progressors, Prog, black; Viremic controllers, VC, blue; Elite controllers, EC, red; Aviremic 
individuals on antiretroviral therapy, ART, gray. Statistics were calculated using Spearman 
correlation. (F) Frequency of RM cells expressing T-bet by cohort. (G) T-bet MFI of plasmablasts 
by cohort. (H) Comparison of transcript expression levels for 91 gene targets between healthy 
donors (n=4) and progressors (n=5). Each dot represents the mean expression value calculated 
for HIV-negative donors (x value) and progressors (y value). Lines represent 90% prediction 
bands of calculated linear regression. Statistical comparisons in B, D, F, and G calculated using 
one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 0.01. ** 
denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001. 
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3.3.3 Sustained T-bet expression in B cells alters the antibody isotype repertoire 
 
As T-bet is associated with specific IgG isotypes (Chapter 2, Figure 2E), we hypothesized that the 
maintenance of elevated T-bet expression in B cells and plasmablasts during HIV infection might 
alter memory B cell surface IgG isotype distribution and serum antibody repertoires in these 
individuals. We therefore analyzed memory B cells from HIV-negative individuals and progressors 
and found increased frequencies of IgG1- and IgG3-expressing memory B cells during HIV 
infection (Figure 10A). To explore possible downstream effects on secreted antibody, we next 
assessed the isotypes of total serum antibody from progressors and age/ethnicity matched HIV-
negative controls and found approximately 2-fold increases in titers of IgG1 and IgG3 in 
progressors as compared to controls (Figure 10B). IgG1 titers in viremic subjects positively 
correlated with the frequency of T-bet+ memory B cells (though this did not reach statistical 
significance due to a single outlier), while IgG2, IgG3, IgG4, and IgA titers displayed no 
relationship (Figure 10C). IgM titers also positively correlated with T-bet expression frequency 
(Figure 10C), suggesting that activation events in early memory B cell differentiation may be 
skewed by T-bet expression. In summary, HIV drives the expansion and maintenance of T-bet+ 
memory B cells and plasmablasts, which correlate with an overrepresentation of surface-
expressed and soluble IgG1 and IgG3 during viremic infection.  
 We next set out to examine the relationship between T-bet activation-induced cytidine 
deaminase (AID, or AICDA as transcript), the B cell-specific enzyme that is required for antibody 
isotype switching (37). Within the peripheral B cell compartment, AICDA expression is highest in 
T-bethighCD85jhigh B cells, and transcript levels remain elevated in this subset during chronic HIV 
infection (Tables 3 and 5; Figure 10D). To examine the potential regulation of AICDA transcript 
expression by T-bet, we performed siRNA-mediated downregulation of T-bet in primary CD21-
CD27- B cells from progressors with high T-bet expression frequencies in this subset (mean 
93.6% T-bet+, range 81.2% to 97.6%; Figure 10E), as previously described (178); cells 
consistently retained their CD85jhigh phenotype following nucleofection (Figure 10F). CD21-CD27-  
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Figure 10: Antibody isotype expression levels, correlations with T-bet, and siRNA T-bet 
knockdown in B cells of progressors. 
(A) Frequency of IgG isotype-expressing B cells within total memory B cell compartment of HIV-
negative individuals and progressors (HIV+) (n=10 donors per group). Statistics in A and B 
calculated using unpaired t-test. (B) Absolute concentration of total serum antibodies by isotype 
from progressor (HIV+) and age/ethnicity-matched HIV-negative cohorts (n=10 donors per group). 
(C) Correlations between T-bet expression frequency in memory B cells and serum antibody titers 
by isotype (ng/ml). Statistics in C calculated using Spearman correlation. (D) AICDA transcript 
expression (log2 units) of HIV-negative donors (grey; n=4) and progressors (black; n=5) per B cell 
subset. Trans., transitional; RM, resting memory; PB, plasmablast. Each dot represents transcript 
expression from one individual. Statistical comparison calculated using repeated measures 
ANOVA with Tukey’s multiple comparisons. (E) Expression of CD21 and T-bet within CD27- B 
cells from a representative progressor used for CD21-CD27- B cell sorting. (F) CD85j expression 
by sorted CD21-CD27- B cells at 24 and 72 hours post-nucleofection with either control or T-bet 
siRNA, compared to non-nucleofected sample. (G) RT-PCR of AICDA transcript in CD21-CD27- B 
cells of progressors transfected with control or T-bet siRNA. Values represent AICDA transcript 
level as a fraction of no siRNA treatment condition. Statistical comparison in G calculated using 
paired t-test. * denotes a P value 0.05 > P ≥ 0.01; ** denotes a P value 0.01 > P ≥ 0.001. 
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Donor ID Cohort Duration Status VL CD4 ct. 
OM10 Toronto >1 year Chronic 22415 132 
OM17 Toronto <6 months Early 440000 660 
OM255 Toronto <6 months Early 18322 370 
OM284 Toronto <3 months Acute 170693 430 
OM5007 Toronto <3 months Acute 24019 440 
OM5031 Toronto <1 year Chronic 13537 330 
OM5037 Toronto <3 months Acute 13948 780 
OM5062 Toronto >6 months Chronic 187361 410 
OM5220 Toronto <3 months Acute 10640 470 
OM5271 Toronto <3 months Acute 25947 320 
P09586 UPenn CFAR 2.5 months Acute 23990 446 
P09588 UPenn CFAR >1 year Chronic 80000 <500 
P09603 UPenn CFAR 67 days Acute 442034 922 
P09636 UPenn CFAR 6 months Early 43374 605 
 
Table 5: Acute and chronic HIV samples from University of Toronto and University of 
Pennsylvania CFAR cohorts. Viral loads and CD4 count for University of Toronto and University 
of Pennsylvania cohorts are depicted. The listed duration of infection is estimated: Acute samples 
are estimated to have been collected <3 months since infection; Early samples are between 3-6 
months since infection; Chronic samples are from greater than 6 months since infection. All 
individuals were therapy-naïve at time of sampling. 
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B cells were chosen as a representation of the T-bethighCD85jhigh population because they can be 
identified and sorted via negative selection, avoiding potential ligation effects of CD85j-specific 
antibodies. T-bet siRNA knockdown reduced levels of AICDA by 44% compared to control siRNA, 
indicating that T-bet at least partially regulates expression of AICDA in this population and may 
promote class switching via this regulation (Figure 10G).   
 
3.3.4 HIV infection primarily drives a T-bet+ B cell response to HIV envelope protein gp140 
 
Finally, we examined the relationship between T-bet+ B cells and the B cell response to HIV, 
focusing on the Env-specific response since this antigen is the relevant antibody target during 
HIV infection (54). Using a group M consensus sequence-derived gp140 protein to capture 
soluble antibody in an ELISA format, we analyzed the isotype repertoire of the gp140-specific 
antibody in serum of progressors (Table 3) and found that, in agreement with previous studies 
(179-184), Env-specific responses are dominated by IgG1 isotype antibodies (Figure 11A), the 
most frequent IgG isotype associated with T-bet-expressing B cells. To directly connect this 
expanded Env-specific IgG1 usage to the cellular component of the response, we used gp140 
protein fluorophore probes to identify gp140-specific B cells via flow cytometry, as previously 
described ((152); Figure 11B). Progressors, several of which were estimated to be in the early 
acute phase of infection, at <3 months HIV+ (see Table 5), demonstrated a mean gp140-specific 
B cell frequency of 0.86% of class-switched B cells in peripheral blood, and this frequency was 
diminished in HIV+ cohorts with lower viremia (Figure 11C). Interestingly, nearly all gp140-specific 
B cells expressed T-bet, regardless of the HIV+ donor’s viral load (Tables 4 and 5; Figures 11D 
and 11E). gp140-specific B cells from HIV viremic individuals consistently demonstrated a T-
bethighCD85jhigh phenotype, while the gp140-specific B cell response in subjects with lower or 
controlled viremia was composed of both T-bethighCD85jhigh cells and T-betlow RM B cells (Figure 
11F and data not shown). Taken together, these findings demonstrate that the humoral immune 
response to HIV Env is specifically coordinated by the T-bet+ memory B cell population and 
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suggests induction of this transcription factor as a mechanism driving the predominantly IgG1-
based Ig response to the virus. 
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Figure 11: gp140-specific memory B cell phenotypes and serum Ig isotypes. 
(A) gp140-specific serum Ig titers by isotype from progressors (n=10). Titers were normalized 
using age/ethnicity matched controls. Statistical comparison calculated using repeated measures 
one-way ANOVA with Tukey’s multiple comparisons test. (B) Representative staining of gp140-
specific class switched (IgD-IgM-) memory B cells from a progressor. (C) Frequency of gp140-
specific cells within total class-switched memory B cells by cohort. n=10 for all cohorts except 
progressors (n=11). (D) T-bet expression of gp140-specific B cells (red) and total B cells (black) 
from a representative progressor. (E) Frequency of T-bet expression within gp140-specific cells 
from HIV+ cohorts (n=10 progressors, n=10 VC, n=6 EC). All donors with <40 gp140-specific cells 
(including all ART individuals) were excluded from analyses in E and F. No statistical differences 
were observed between donor groups. (F) Frequency of gp140-specific cells with T-
bethighCD85jhigh phenotype by cohort. For C, E, and F, statistical comparisons were calculated 
using one-way ANOVA with Tukey’s multiple comparisons test. * denotes a P value 0.05 > P ≥ 
0.01; ** denotes a P value 0.01 > P ≥ 0.001. *** denotes a P value < 0.001. 
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3.4 Discussion 
 
The identity of the cells and regulatory mechanisms orchestrating the humoral HIV response has 
remained unclear. We tested the hypothesis that T-bet+ B cells, which expand during acute 
resolving viral infections and express antiviral antibody isotypes, contribute to the HIV response. 
Similar to YFV and VV vaccinations, acute HIV infection elicits an expansion of T-bet+ B cells; 
however, unlike the transient nature of acute YFV and VV responses, chronic HIV viremia 
maintains elevated T-bet+ B cell frequencies that are associated with increased serum IgG1 and 
IgG3 titers. These T-bet+ cells dominate the HIV Env-specific B cell response and likely skew the 
anti-Env serum antibody repertoire to the IgG1 isotype.  
In agreement with our previous study of HIV- donors (Chapter 2), our current 
observations of increased IgG1+ and IgG3+ memory B cell frequencies in viremic HIV+ donors 
maintaining elevated T-bet expression further support T-bet as a mechanism promoting IgG1 and 
IgG3 isotype switching. Memory B cells do not actively secrete antibody; however, viremic HIV+ 
individuals also displayed increased T-bet MFI in plasmablasts, increased total IgG1 and IgG3 
serum titers, and an IgG1-dominated Env-specific serum antibody response, suggesting IgG1+ 
and IgG3+ antibody-secreting cells readily differentiate from or share a similar origin with IgG1+ 
and IgG3+ memory B cells. It is unclear why IgG3 antibodies are not more prevalent within the 
anti-Env antibody repertoire during chronic HIV infection when T-bet expression is high, but IgG3 
levels have been demonstrated to peak early during HIV infection and wane over time (54). It is 
possible that sustained HIV viremia drives recurrent germinal center re-entry and isotype 
switching of memory B cells, which could promote splicing out of the proximally located γ3 gene 
from the constant region locus as the infection progresses; indeed, a recent study suggests class-
switching of IgG3+ B cells would likely give rise to either IgG1+ or IgG2+ cells (185). Together, our 
findings suggest T-bet expression in B cells coordinates the IgG1-dominated anti-Env response 
and likely regulates antibody isotype selection during other human viral infections. 
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 AID expression is tightly controlled by multiple factors (38), but our siRNA T-bet 
knockdown experiments suggest that T-bet may regulate IgG1 and IgG3 class switching in part 
by promoting AICDA expression, although it is unclear whether this occurs by direct or indirect 
mechanisms. In addition to isotype switching, AID is required for somatic hypermutation (37), the 
diversification of antibody binding sites. Therefore, by regulating AICDA, T-bet may also promote 
antibody mutation, and a recent murine study supports this notion by demonstrating significant 
mutation rates in BCRs from T-bet-expressing B cells (186). However, antibody mutation may be 
impaired in subsets of T-bet+ B cells during progressive HIV infection, as HIV-specific antibodies 
derived from TLM cells demonstrated diminished mutation levels compared to RM cell-derived 
antibodies (187). Future studies should examine whether relatively low TLM antibody mutation 
rates are typical (i.e. observed in healthy individuals mounting successful humoral responses) or 
are instead reflective of immunopathology specific to chronic HIV infection; in support of the latter 
possibility, malaria-specific antibody derived from TLM-phenotype B cells displayed higher 
mutation rates than those derived from RM cell counterparts (188).  
HIV+ cohort analyses identified involvement of both T-bethigh (CD21-T-bethighCD85jhigh) 
and T-betlow (CD21+CD27+T-betlow) B cell subsets in the HIV response, with potentially divergent 
roles. T-bethigh cells were induced early and maintained the Env-specific B cell response during 
chronic viremic HIV infection, with a reduction in T-bethigh population size following natural or 
therapy-mediated control of viremia. Combined with our YFV and VV observations (Chapter 2), 
these findings suggest T-bethigh cells are a major component of acute and chronic antiviral B cell 
responses and, in the setting of HIV, are responsive at a population level to modulation of viremia 
and immune activation. Conversely, reduction of viremia during chronic HIV infection did not 
affect expanded T-betlow RM cell population size, suggesting these cells do not depend on viral 
replication for their maintenance. Viral control was also associated with a greater representation 
of T-betlow cells within the Env-specific pool, suggesting the Env-specific response is mediated by 
different T-bet+ B cell subsets depending on disease course: T-bethigh cells during acute infection 
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and settings of high viremia, and T-betlow B cells in the context of controlled but persistent low 
level viremia. 
We and others have previously demonstrated an expansion of CD21- B cell subsets 
induced by Th1-type human infections, including HIV, Malaria, and Hepatitis C (120, 150, 151, 
160, 161, 165, 189, 190), and expansion of a clonal CD21- subset has been described during 
Hepatitis B- and Hepatitis C-associated mixed cryoglobulinemia (191-193). Interestingly, 
maintenance of expanded CD21- cells in each of these infections appears to be dependent upon 
pathogen load (150, 151, 189, 194-196). Our current findings, combined with the similar CD21- B 
cell phenotypes described in these studies, suggest that CD21- B cell expansion associated with 
these various Th1-type infections may in part be explained by infection-induced T-bet expression 
and expansion of T-bethighCD85jhigh cells. In support of this hypothesis, murine experiments 
suggest the T-bet+ B cell phenotype is induced by concerted actions of pathogen-derived nucleic 
acids (TLR7 or TLR9 stimulation; (113-117, 197)) and cytokines produced during Th1-type 
infections (IFNg and IL-21; (65, 78, 116)) on B cells. Still, additional studies are necessary to 
determine the relationship between acute viral infection-induced T-bethighCD85jhigh cells and these 
chronic infection expanded CD21- B cell subsets. Interestingly, observational human studies 
further demonstrate similar CD21- B cell expansion during various autoimmune diseases (73, 
119, 121, 162, 163, 166), and murine models indicate TLR sensing can stimulate T-bet 
expression to drive expansion of autoantibody-producing B cells (78, 115), suggesting CD21-T-
bet+ B cells may also play a role in human autoimmune diseases.  
 While our YFV and VV acute infection observations (Chapter 2) suggested T-bet+ B cells 
generally represent a component of the antiviral B cell response, we specifically demonstrated 
that T-bet+ B cells compose nearly the entire detectable peripheral B cell HIV Env memory 
response, beginning at least during early (<3 months HIV+) infection. As such, most gp140-
specific antibodies likely derive from descendants of the T-bet+ B cell population or share a 
similar T-bet-regulated origin in both progressors and individuals controlling viremia. This likely 
also includes HIV-specific broadly neutralizing antibodies, but requires further assessment as 
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previous studies that isolated broadly neutralizing antibodies from B cells generally did not 
consider the nature of the cells. An important question remaining is the degree to which T-bet+ B 
cells and derived antibodies contribute to control of viremia during HIV and other viral infections. 
Indeed, while a murine study demonstrated the requirement of T-bet+ B cells to control chronic 
LCMV viremia to low levels (118), the role of B cells and immunoglobulin in ongoing control of 
HIV/SIV remains controversial (198-202). However, it is highly likely that an efficacious HIV 
vaccine will need to induce HIV Env-specific broadly neutralizing antibodies.  As such, our results 
directly demonstrate the importance of T-bet-expressing B cells to the HIV-specific humoral 
response.  
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CHAPTER 4 
	  
CONCLUSIONS, IMPLICATIONS, AND FUTURE DIRECTIONS 
 
Introduction 
 A more complete understanding of B cell biology is critical for the development of 
vaccines and other interventions to improve humoral immunity to viruses, particularly in the case 
of HIV infection. As such, we sought to better define the cellular members and mechanisms that 
directly promote human antiviral responses and help to maintain humoral memory. In chapters 2 
and 3 of this dissertation, we identified a previously unappreciated T-bet-expressing B cell 
population and described a number of characteristics, including cell phenotypes, population 
dynamics, and tissue localization, that identify human T-bet+ B cells as a unique viral infection-
responsive subset. Our findings provide critical insights into the T-bet-regulated generation of 
humoral viral responses, identify T-bet+ B cells as the specific mediators of the HIV Env 
response, and raise a number of questions that provide a framework for further dissecting the 
biology of human T-bet+ B cells. The conclusions, implications, and future directions of this 
dissertation’s key findings will be discussed below. 
 
T-bet as a mediator of Th1 immunity in human B cells 
 Recent murine studies demonstrate a role for T-bet-expressing B cells in viral control 
(117, 118), but the mechanisms driving antiviral immunity in human B cells are poorly understood. 
Our observed induction of T-bet expression across the B cell compartment during diverse acute 
viral infections (low versus high viremia and inflammation; RNA versus DNA viruses) and chronic 
HIV infection strongly suggests a role for T-bet as a critical regulator of antiviral humoral immunity 
in humans. T-bet’s association with IgG1 and IgG3 antibody isotypes in both HIV- individuals and 
those mounting a substantial HIV immune response identifies promotion of class switching as an 
important function mediated by the transcription factor to combat viruses. Our findings further 
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suggest that T-bet expression promotes the differentiation of a unique activated B cell subset to 
mediate the acute antiviral response and maintains a resting memory pool prepared to initiate 
secondary immune responses (discussed further below). Via these diverse mechanisms, T-bet 
appears to broadly coordinate humoral antiviral immunity in humans. 
 The substantial induction of T-bet during acute viral responses, particularly in the T-bethigh 
subset, suggests T-bet may act as a master regulator of Th1-type B cell development. However, 
it is unclear whether T-bet is sufficient to drive Th1 B cell development in humans or is simply a 
marker of this program, acting as a minor player within a larger transcriptional network. In support 
of the former possibility, T-bet controls a broad transcriptional program in T cells and is required 
for both Th1 CD4+ T cell development and the generation of IgG2a+ B cell responses in mice (78, 
99). Our findings suggest human B cell development mirrors that of CD4+ T helper cell 
differentiation (i.e. Th1 vs. Th2) in which cytokines and other signals guide specific differentiation 
pathways at the expense of others (203). Subsequent analyses of T-bet+ B cell differentiation, 
polarization, and plasticity will be best explored in murine models. 
 The exclusivity of T-bet in regulating human B cell immune responses to viruses versus 
other pathogens is an important question that has not been assessed. The expansion of cells 
resembling our T-bethigh population in other Th1 infections such as malaria suggests T-bet 
functions more broadly to promote humoral responses to intracellular pathogens (160). 
Additionally, IL-4 inhibits the T-bet transcriptional program in murine B cells, suggesting T-bet is 
not involved in Th2 B cell responses (116). Future work should assess T-bet induction and T-
bethigh cell activation in the context of non-viral Th1 infections and also infections predicted to 
poorly elicit Th1 immunity, such as encapsulated bacteria or helminthes, to definitively define the 
pathogen responses T-bet regulates. Lastly, it should be noted that our findings suggesting an 
overwhelmingly T-bet-mediated humoral response to human viral infections do not rule out the 
involvement of T-bet- subsets in aspects of the response. 
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T-bethigh B cells as a novel antiviral population 
 In another central finding of this study, we identified a novel T-bet+ viral infection-
responsive subset of memory B cells in healthy individuals. A number of observations support the 
hypothesis that T-bethigh B cells are primed for acute viral infection responses: T-bethigh cells are 
enriched for IgG1 and IgG3 isotypes in healthy individuals, express a distinct trafficking receptor 
profile potentially facilitating tissue and inflammation-directed migration, demonstrate an activated 
phenotype and propensity to expand 2-4 weeks after infection with live replicating viral vaccines 
or HIV, expand and contract in concert with viremia during HIV infection, and dominate the HIV 
Env-specific B cell response in viremic HIV+ progressors. Many of T-bethigh cells’ distinctive 
characteristics mirror those of effector T cells (100), suggesting T-bethigh cells are the specific B 
cell subset mediating the active humoral response to acute human viral infections (Figure 12).  
 Our study further suggests that T-bethigh cells are not a subset of classical memory B cells 
or antibody-secreting cells; instead, based upon their distinct transcriptional and phenotypic 
profiles and immune response kinetics compared to resting memory (RM) B cells and 
plasmablasts, they are likely a separate type of cell within the B cell lineage. This notion is 
supported by phylogenetic studies of CD21low B cells that identified both distinct CD21low clades 
and clonal relationships between these cells and the RM cell and plasmablast populations (204). 
T-bethigh cells’ functional niche within the human humoral immune system is still unclear, but our 
transcriptional analyses identified intermediate expression of antibody-secreting program-
promoting transcription factors (IRF4, PRDM1, and XBP1), suggesting these cells may be primed 
to quickly differentiate into antibody-secreting cells and contribute to the antibody response. Their 
distinctive trafficking receptor profile further suggests specialized migratory capacity, and murine 
studies suggest they may be capable of producing cytokines such as IFNg upon stimulation (65). 
Future analyses should focus on elucidating the specific functions mediated by T-bethigh B cells 
during acute viral infections. 
 We also identified a unique tissue compartmentalization of T-bethigh cells: unlike 
plasmablasts and RM cells, which were identified in lymphoid tissues and can re-circulate back  
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Figure 12: Model proposing the induction and differentiation of T-bet-expressing B cells by 
viral infections.  
T-bet is induced in B cells by TLR/cytokine/BCR stimulation during acute viral infection, leading to 
T-bethigh cell development. Upon viral clearance (yellow fever virus (YFV) and vaccinia virus (VV) 
vaccinations), the blood T-bethigh subset contracts in size, potentially due to trafficking of cells into 
tissues, differentiation into a resting phenotype (T-betlow), or cell death. However, during chronic 
HIV infection, persistent viral replication and immune activation induce expansion and 
maintenance of a large T-bethigh B cell pool that will return to normal size only upon control of 
viremia via antiretroviral therapy (ART). 
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into the blood, T-bethigh cells appear to be largely absent from lymphoid tissues (except for a 
curious T-bethighCD21+ population in the spleen) and, based upon their absence from thoracic 
duct fluid, may not return back into the blood after they exit. Together, these observations 
suggest T-bethigh cells do not re-circulate in the absence of a significant immune response and 
raise questions regarding their trafficking and tissue localization. CD11c and CXCR3 expression 
would be predicted to enable tissue trafficking toward sites of inflammation, so T-bethigh cells may 
migrate from the blood directly into tissues where infection occurs. However, our data suggests T-
bethigh cells do not return to the blood and instead may either reside permanently in these tissues 
or undergo apoptosis after completion of the acute immune response (Figure 12). Regardless, T-
bethigh cells’ tissue distribution and circulatory patterns indicate that lymphoid tissue immune 
surveillance (analogous to that of naïve and RM cells) is not a primary function of this subset.  
 Our findings are complemented and informed by two recent studies of early acute 
antigen-specific responses to infection and vaccination (159, 204). The first by Ellebedy et al. 
identified an activated, CD21low B cell subset expressing CD71 that emerged acutely following 
influenza infection, ebola infection, and influenza vaccination, and contained the majority of 
influenza-specific B cells (159). While the second by Lau et al. did not detect a clear population 
expansion, the authors found a concentration of influenza-specific cells in the CD21low population 
acutely following vaccination and an enrichment of T-bet expression in CD21low- and RM-
phenotype hemagglutinin-specific cells (204). In both cases, the cells’ CD21low phenotype and 
population dynamics during the acute immune responses suggest they are likely T-bethigh B cells. 
Together, these studies extend our findings of T-bethigh cell activation in primary YFV, VV, and 
HIV infections by implicating a broader involvement of T-bethigh cells in influenza and Ebola 
responses and suggesting T-bethigh cells can also be activated during secondary responses 
(influenza) and by non-replicating viruses (inactivated influenza vaccine).  
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T-betlow B cells as a quiescent memory population 
 In addition to Tbethigh cells, our study identified a counterpart T-betlow subset within the 
RM B cell population. As their name suggests, T-betlow cells express T-bet at a low MFI that is 
difficult to confidently detect using most intracellular cytokine staining protocols. This population 
differs significantly from Tbethigh cells in a number of other phenotypes and behaviors, including 
consistent CD21 and CD27 expression, minimal signs of activation, an unresponsiveness to 
acute viral infections in terms of activation and expansion (at the population level), and a 
widespread lymphoid tissue distribution with the ability to re-circulate back into the blood. These 
characteristics are largely consistent with a resting, long-lived memory B cell phenotype (151); as 
such, we speculate that T-betlow cells represent a reservoir of virus-specific clones that function to 
maintain long-lived humoral memory to viral infections and facilitate rapid responses upon antigen 
re-encounter. The existence of a human T-betlow memory population is supported by mouse 
models in which IgG2a+ memory B cells require consistent low-level T-bet expression to maintain 
their integrity well after class-switching has completed (112). 
 If T-betlow cells are indeed a resting, virus-specific reservoir, T-bethigh cell clones 
generated early during acute viral infection would be predicted to seed the T-betlow population 
upon resolution in the contraction phase (Figure 12). In support of this phenomenon, influenza-
specific, acutely activated CD21low clones have been demonstrated to enter the long-lived 
memory pool (159), and common origins of pathogen-specific TLM (CD21-CD27-; almost certainly 
T-bethigh cells based on our findings) B cells and RM cells have been described during HIV 
infections (187). In our own study, the T-betlow population increasingly maintained the Env-
specific memory B cell pool upon control of viremia and subsequent contraction of the T-bethigh 
subset, and T-betlow cells’ maintenance in the absence of detectable HIV viremia suggests an 
ability to survive independent of antigen and significant inflammatory signals.  
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Plasmablasts can express T-bet 
 Previously, Wang et al. described low-level T-bet mRNA expression in plasmablasts 
during a hapten response in mice (112). To our knowledge, ours was the first study to identify T-
bet protein expression in plasmablasts. T-bet was essentially undetectable in the plasmablasts of 
healthy individuals in the absence of an immune response; however, YFV- and VV-vaccinated 
individuals reproducibly exhibited a significant spike in plasmablast T-bet MFI that peaked around 
2 weeks post vaccination but remained lower than the MFI in T-bet+ memory B cells. T-bet MFI in 
plasmablasts also increased during acute HIV infection and was maintained at an elevated MFI in 
chronically infected individuals, suggesting T-bet induction may contribute to the IgG1-focused 
hypergammaglobulinemia characteristic of viremic HIV infection. T-bet’s function in plasmablasts 
is unclear, but it may be required for the continuous transcription of IgG1 and IgG3 that would 
occur in cells constitutively producing antibody (112). T-bet may also help plasmablasts traffic to 
sites of inflammation by promoting CXCR3 expression.  
 
Human spleen is a T-bet+ B cell-rich organ 
 Our identification of a massive CD21+T-bet+ B cell population in human spleen was 
particularly surprising since the magnitude more closely resembled reactive lymph nodes than the 
non-reactive nodes assessed in our study (123). It remains possible that this phenomenon is the 
result of unrecognized inflammation in our spleen samples, but the consistently large CD21+T-
bet+ population in all six donors suggests this is a common phenotype. Our panel was insufficient 
to determine the identity of these cells and their relationship to peripheral T-bet+ subsets, but they 
were chiefly comprised of cells with marginal zone B cell-like (CD21+CD27+IgM+IgD+) and class-
switched memory-like (CD21+CD27+IgM-IgD-) phenotypes. Interestingly, we also detected T-bet 
expression in phenotypically naïve cells (CD21+CD27-IgD+), suggesting the spleen may be a site 
of T-bet+ B cell activation. The considerable population size of splenic CD21+T-bet+ B cells 
suggests a portion of these cells may be spleen-resident, raising the possibility that human 
spleen acts as a reservoir of T-bet+ B cells. Histological, transcriptional, and phylogenetic studies 
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are necessary to identify the localization of these cells (white pulp, red pulp, or marginal zone) 
and determine their relationship to peripheral blood T-bet+ B cells. 
 
Tissue-like memory B cells are not inherently dysfunctional 
Our data identify an association between T-bethigh B cell induction and protective vaccine-
induced antibody responses, and this connection is further supported by influenza studies (159, 
204) and T-bet+ B cells’ clear association with control of viral load in mice (117, 118). Together, 
these studies suggest T-bethigh cells are not a functionally impaired developmental aberration and 
are instead a normal component of acute humoral responses. This notion has implications for the 
HIV-specific B cell response (discussed below), but it also contradicts a prevalent conviction that 
tissue like memory (TLM) cells, a large component of the T-bethigh population, are inherently 
dysfunctional (151). Expansion of this normally rare population during chronic infectious diseases 
(120, 151, 160) and autoimmune diseases (73, 119, 162, 163) is generally interpreted as 
evidence of an aberrant differentiation state, and in some cases such as SLE, these cells do 
contribute to pathology (119). However, in the context of HIV infection, our findings suggest that 
T-bethigh (and TLM) cell expansion is a product of uncontrolled viral replication and inflammation 
continuously directing newly activated B cells along the T-bethigh differentiation pathway. Since T-
bethigh population size returns to normal upon control of viremia, we propose that HIV is simply 
driving the consistent development of a normally transient population. Importantly, our findings do 
not rule out the possibility that T-bethigh B cells with a TLM phenotype effectively participate in 
acute viral responses but specifically undergo exhaustion and become dysfunctional if they are 
abnormally maintained for an extended period of time in the presence of high antigen load (205). 
Functional studies comparing T-bethigh cells in HIV- and HIV+ individuals are necessary to 
definitively rule out this possibility, but our phenotypic and transcriptional comparisons in these 
cohorts suggest T-bethigh cells themselves are largely unchanged by chronic infection. 
Several TLM cell characteristics interpreted to reflect dysfunction or anergy can be 
explained by the biology of the T-bethigh B cell subset. First, TLM cells poorly respond to 
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traditional BCR-based stimulation in vitro (151). This property has been confirmed in murine 
models, which suggest T-bet+ B cells are a subset with distinct requirements for activation. 
BCR/CD40 stimulation poorly activates mouse T-bet+ B cells, while BCR and concomitant TLR7 
and TLR9 stimulation potently drive activation of this subset (114, 115). Analyses of human TLM 
B cells have largely failed to assess these combinations known to efficiently activate T-bet+ B 
cells and may therefore misrepresent the cells’ capacity for responsiveness. In combination with 
IFNg and IL-21, TLR7 and TLR9 stimulation also efficiently drive T-bet+ B cell differentiation from 
precursors (116), suggesting HIV infection likely induces T-bet in human B cells by directly 
providing TLR7 and TLR9 ligands (206-210) and indirectly stimulating production of Th1-
associated cytokines (IL-12, IL-15, IL-18, TNF, and IFNg) during both acute and chronic phases 
of infection (211-213).  
Second, TLM cell-derived HIV Env-specific antibodies have been described as inferior, 
demonstrating decreased somatic hypermutation and HIV neutralization capacity compared to 
resting memory B cells (187). In line with this observation, analyses of human CD27-IgG+ B cells 
(a large component of the TLM population) and CD21low cells strongly suggest T-bethigh (and 
TLM) cells are relatively recent germinal center emigrants and, as such, would be expected on a 
population level to demonstrate reduced affinity maturation compared to the mature resting 
memory pool (72, 73, 204). It remains possible that TLM-phenotype cells exhibit HIV infection-
specific antibody maturation deficits due to impaired B cell help, but antibodies derived from 
Plasmodium falciparum-specific TLM B cells are highly mutated and neutralize comparably to 
antigen-specific resting memory B cell counterpart (188), suggesting diminished antibody 
mutation is not necessarily characteristic of TLM-phenotype cells. 
Lastly, with regard to the aforementioned points, it becomes difficult to extrapolate from 
TLM B cell findings and relate these to T-bethigh cells as most TLM B cell studies are complicated 
by CD21-CD27- population heterogeneity: we and others identified significant differences between 
the T-bet+ and T-bet- subsets that together comprise the TLM B cell population (171), but studies 
have generally assessed the TLM population as a whole. Accordingly, future analyses should 
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specifically focus on the characteristics of the T-bet+ TLM B cell population to understand the role 
of TLM B cells during infection. 
 
T-bet+ B cells dominate the memory B cell response to HIV Env 
 Our surprising identification of T-bet+ B cells as mediators of the HIV Env response is a 
critical finding that generates a number of questions and holds implications for HIV immunity and 
vaccine efforts. This observation definitively confirms T-bet+ B cells as mediators of humoral 
antiviral responses, a concept that was implicated by our YFV and VV response data, and further 
suggests T-bet induction as the mechanism promoting an IgG1-focused Env-specific antibody 
response in HIV-infected individuals. An important question remaining is the degree to which 
expanded T-bet+ B cells in infected individuals are virus-specific, as our HIV gp140 probe cannot 
capture all Env-specific cells and B cell responses generated against other HIV proteins such as 
Gag were not assessed. HIV infection is characterized by polyclonal B cell activation (147), and 
the excessive magnitude of T-bet induction suggests bystander activation may contribute to the 
expanded T-bet+ B cell population, but our findings indicate that the T-bet-regulated response is 
at least partially virus-specific.  
 As T-bet induction in B cells is critical for control of murine viral infections and associates 
with protective vaccine responses in humans, we originally hypothesized that an inability to mount 
a T-bet+ B cell response might partially explain the shortcomings of humoral immunity during HIV 
infection. However, our identification of a Th1-biased, T-bet-regulated B cell and antibody 
response in both viremic and controlling individuals suggests the humoral immune system 
mounts an appropriately focused B cell response to HIV Env, even in settings of 
immunopathology. While B cell development does not seem to be misdirected by HIV per se, a 
number of other HIV infection-related factors may impede the T-bet-regulated response and 
prevent timely development of broad neutralization, including loss of CD4+ T cell help, disruption 
of lymphoid tissue architecture, and the difficult antigenic nature of the virus.  
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 Humoral immunity (and T-bet+ B cells by extension) cannot effectively neutralize and 
clear HIV in infected individuals. However, as antibodies can put significant pressure on the virus 
(138, 140, 214), an important question remaining is whether T-bet+ B cells can still contribute to 
the HIV immune response. T-bet+ B cells and their antibodies are critical for maintaining low level 
chronic viremia in mouse models (117, 118), and several human and macaque B cell depletion 
studies demonstrate a loss of HIV/SIV set point control upon B cell and neutralizing antibody titer 
decline (198, 200, 202), together suggesting that the T-bet+ B cell-mediated antibody response 
may contribute to the maintenance of set point viremia in some cases. A tractable model would 
be necessary to decisively determine this, but human studies assessing the relationship between 
T-bet induction and immunological or disease outcomes may provide insight into T-bet’s potential 
role in the immune response (e.g. does an earlier B cell T-bet response or one of greater 
magnitude correlate with viral set point or development of neutralization breadth?). In any case, 
our findings suggest that any humoral immunity-based pressure on the virus is likely derived from 
T-bet+ B cells and the HIV Env antibody response they regulate. 
 
Considerations for vaccines 
 Perhaps most importantly, our findings identify both T-bet itself and T-bet+ B cells 
(particularly the T-bethigh subset) as targets of interest for vaccines and therapeutic interventions 
attempting to induce or manipulate Th1-focused humoral immunity. Similarly, T-bet induction in B 
cells could serve as a reliable biomarker to assess vaccine candidates’ ability to drive Th1 B cell 
programs. Recent immune correlates analyses of the RV144 HIV vaccine trial identified an 
association between the elicitation of IgG3-isotype antibodies and reduced infection risk (215, 
216), suggesting T-bet induction may be directly relevant to future vaccine efforts attempting to 
consistently recreate this response. TLR7/8 and TLR9 adjuvants may hold promise for promoting 
T-bet-regulated vaccine responses, and a number of studies show that these adjuvants 
significantly improve the quality of antibodies generated by vaccination (217, 218). In summary, a 
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more detailed understanding of T-bet+ B cell biology will be informative for the development of 
interventions to improve humoral immunity to viruses. 
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CHAPTER 5 
MATERIALS AND METHODS 
 
Study participants: 
 Acute infection studies: Five healthy, HIV-negative individuals received live-attenuated 
YFV-17D vaccine (YF-Vax, Sanofi Pasteur) and seven different healthy, HIV-negative individuals 
received live vaccinia smallpox vaccine (Dryvax, Wyeth Laboratories). Peripheral blood 
mononuclear cell (PBMC) samples were obtained on or near day of vaccination and at several 
subsequent time points (see Table 1 for donor information). Seven acutely infected HIV+ donors 
were enrolled in the RV217 Early Capture HIV Cohort run by the US Military HIV Research 
Program. PBMC sample timing was calculated relative to first positive HIV RNA test (Abbot Real-
Time HIV-1 assay, Abbot Laboratories, Abbott Park, IL). Samples included a pre-infection time 
point (ranging 478-41 days previous to first positive HIV RNA test.), an early acute infection time 
point (ranging 1-21 days after first positive test; these were collected during or shortly after peak 
acute viremia and are considered to represent an early acute infection time point), and a chronic 
infection time point (see Table 2). Individuals were antiretroviral therapy-naïve at all sample time 
points assessed.  
 
Tissue studies: Paired blood and thoracic duct fluid samples were obtained from individuals with 
idiopathic or trauma-based chylopericardium or chylothorax requiring intervention at the Hospital 
of the University of Pennsylvania. Lymphoid tissue samples (mesenteric lymph node, iliac lymph 
node, tonsil, and spleen) were obtained at the Hospital of the University of Pennsylvania and 
Case Western Reserve University: mesenteric and iliac lymph nodes were obtained as normal 
structures during abdominal surgery and kidney transplant surgery, respectively. Non-enlarged 
tonsils were obtained from sleep apnea patients. Spleens were removed and obtained due to 
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trauma or surgical intervention. Mononuclear cells were mechanically separated from solid 
tissues and enriched using a ficoll gradient.  
 
Chronic HIV infection studies: PBMCs and serum from ART-naïve, viremic HIV+ individuals 
(referred to as progressors) and PBMC from ART-treated, aviremic HIV+ individuals (referred to 
as ART) were obtained from the University of Pennsylvania Center for AIDS Research (CFAR; 
see Supplementary Tables 1 and 3). HIV-negative serum samples age- and ethnicity-matched to 
the ART-naïve, viremic HIV+ individuals were obtained from Case Western Reserve University. 
PBMCs from viremic controllers and elite controllers (VC and EC, respectively) were obtained 
from individuals enrolled in the SCOPE study at the University of California San Francisco (see 
Supplemental Table 2). Additional progressor PBMCs were obtained from the University of 
Toronto (see Supplemental Table 3). Healthy HIV-negative human donor PBMC samples were 
obtained from the University of Pennsylvania Human Immunology Core.   
 
Antibody reagents: 
 The following antibodies were obtained from Biolegend: CD19 BV785 (clone HIB19), 
CD3 APC-Cy7 and BV570 (clone UCHT1), IgM BV605 (clone MHM-88), CD21 PECy7 (clone 
Bu32), CD27 BV650 (clone O323), CD38 BV421 and BV711 (clone HIT2), CXCR3 BV711 and 
APC (clone G025H7), CD86 BV605 (clone IT2.2), CD10 BV605 (clone HI10a), CD71 FITC (clone 
CY1G4), PD-1 BV421 (clone EH12.2H7), CD8 BV711 (clone RPA-T8), CD56 BV605 (clone 
5.1H11), CD16 PECy5 (clone 3G8). The following antibodies were obtained from BD 
Biosciences: CD14 APC-Cy7 (clone MØP9), CD16 APC-Cy7 (clone 3G8), IgD PECF594 and 
AF700 (clone IA6-2), IgG AF700 (clone G18-145), CD85j FITC (clone GHI/75), Ki67 AF700 and 
FITC (clone B56), CD21 BV421 (B-ly4), CD95 PECy5 (clone DX2), Bcl-6 PE (clone K112-91). 
The following antibodies were obtained from eBiosciences: T-bet PE and PECy7 (clone 
eBio4B10), CD10 PECy5 (clone eBioCB-CALLA), CD11c PECy5.5 (clone 3.9), CD85j APC (clone 
HP-F1), CD7 PECy7 (clone 124-1D1), Eomesodermin AF647 (clone WD1928). CD69 PECy5 
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(clone TP1.55.3) was obtained from Beckman Coulter. The following antibodies were obtained 
from Southern Biotech: IgG1 PE (clone HP6001), IgG2 AF488 (clone HP6002), IgG3 AF647 
(clone HP6050). IgA FITC (polyclonal) and CD4 PECy5.5 (clone S3.5) were obtained from 
Invitrogen. FcRL4/5 antibody (clone 2A6) was gifted by Max D. Cooper (Emory University, 
Atlanta); this antibody was initially characterized as FcRL4-specific, but a recent study 
demonstrated clone 2A6 reacts with both FcRL4 and FcRL5 (56). 
 
Antibody staining, flow cytometry acquisition, and analysis: 
 Cryopreserved PBMCs (or mononuclear cells from other tissues) were thawed, counted, 
examined for viability, and rested overnight at 37°C and 5% CO2 in RPMI with 10% fetal bovine 
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin added. All incubations 
during the following staining process were performed at room temperature in the dark. On the 
following morning, PBMCs were washed with PBS and stained for viability with aqua amine-
reactive viability dye (Invitrogen) for 10 minutes. Cells were stained with a prepared cocktail of 
surface antibodies for 25 minutes, washed once with PBS plus 0.1% sodium azide and 1% BSA, 
and fixed/permabilized using the eBiosciences FoxP3 Transcription Factor buffer kit (cat# 00-
5523-00). Intracellular targets were stained with a separately prepared cocktail of antibodies for 
60 minutes, washed with the eBioscience kit buffer, fixed with PBS plus 1% paraformaldehyde, 
and stored in the dark at 4°C until acquisition. RV217 cohort samples (Figures 2G, 2H) were 
stained identically except BD Cytofix/Cytoperm Kit (Cat. # 554722) was used to fix/permeabilize 
cells for intracellular staining. Compensation controls were produced with antibody capture beads 
(BD Biosciences) for each antibody and ArC Amine Reactive beads (ThermoFischer Scientific) 
for aqua amine-reactive dye. All flow cytometry data was collected on a modified LSR II (BD 
Immunocytometry Systems). Data was analyzed using FlowJo software (TreeStar). Graphs were 
created and statistical analysis was performed using GraphPad Prism (version 7.0a).  
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HIV gp140 probe staining: 
 Recombinant group M consensus gp140 protein was produced and conjugated to Brilliant 
Violet 421 and Alexa Fluor 647 fluorophores, as previously described (152, 219). Washed 
PBMCs were pre-treated with anti-CD4 (clone SK3, Biolegend) previous to aqua amine-reactive 
dye staining to prevent interactions between gp140 probe and CD4. gp140 probe was then added 
to surface marker cocktail and staining procedure was completed as described above. 
 
Serum antibody characterization:  
 HIV-1 specific and total IgG1- IgG4, IgA and IgM were measured on a Bio-Plex 
instrument (Bio-Rad) as previously described (136, 215, 220). gp140-specific antibodies were 
captured using the same group M consensus sequence protein from gp140-specific cell staining 
(see above).  
 
Cell sorting and Fluidigm Biomark transcript analysis: 
 PBMCs from HIV-infected and –uninfected patients were thawed and rested overnight. 
After being washed in PBS, the cells were incubated with amine-reactive viability dye for 10 
minutes and stained with an undiluted cocktail of surface antibodies at room temperature. Cells 
were washed and resuspended in R10. One hundred cells each from different B cell populations 
were sorted on a FACS Aria II (BD Biosciences) into individual wells of a 96-well PCR plate 
according to the gating strategy depicted in supplemental figure 1A. Each well contained 5 µL 
lysing buffer, consisting of 4.725 µL of DNA Suspension Buffer (10 mM Tris, pH 8.0, 0.1 mM 
EDTA; TEKnova), 0.025 µL of 20 U/µL SUPERase•In™ (Ambion) and 0.25 µL of 10% NP40 
(Thermo Scientific). After FACS sorting, PCR plates were frozen and kept in -80°C until usage. 
PCR plates were thawed on ice and pre-heated for 90 seconds at 65°C. Subsequently, 1 µL 
Reverse Transcription Master Mix (Fluidigm) was added to each well and placed into a 
thermocycler for reverse transcription (25°C for 5 min, 42°C for 30 min, 85°C for 5 min). Next, 4 
µL of a pre-amplification mix, consisting of 1 µL pooled mixture of all primer assays (500nM), 2 µL 
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5× PreAmp Master Mix (Fluidigm) and 1 µL H2O, was added to each well and run on a 
thermocycler (95°C for 5 min followed by 18 cycles: 96°C for 5 sec 60°C for 6 min). To remove 
excess primers, 4 µL of an Exonuclease mixture, containing 0.8 µL 20 units/µL of Exonuclease I 
(New England BioLabs), 0.4 µL 10× Exonuclease I Reaction Buffer (New England BioLabs), and 
2.8 µL H2O was added to each well. The plate was run on a thermocycler (37°C for 30 min, 80°C 
for 15 min). Each well was then diluted (1:4) with DNA Suspension Buffer (10 mM Tris, pH 8.0, 
0.1 mM EDTA; TEKnova). In a new PCR plate, distinct primer assays were generated by adding 
individual primer pairs (5µM) together with a mix of 2.6 µL 2x Assay Loading Reagent (Fluidigm) 
and 2.4 µL 1x DNA suspension buffer to each well. Similarly, a sample PCR plate was created by 
dispensing 4 µL of a sample master mix containing 3.5 µL 2x Sso Fast EvaGreen Supermix with 
Low ROX (Bio-Rad), 0.35 µL 20x DNA Binding Dye Sample Loading Reagent (Fluidigm) and 0.15 
µL H2O to each well. An additional 3 µL of pre-amplified samples were added to each well. 
Control line fluid (Fluidigm) was injected to the 96.96 Dynamic Array chip (Fluidigm) and the chip 
was primed using an IFX Controller HX. After priming the chip, 4.5 µL of the primer assays and 5 
µL of the sample mix were added to detector inlets of the chip and transferred to the IFX 
Controller HX for loading the mixtures. The chip was then transferred to a Biomark HD instrument 
(Fluidigm) and run using the GE Fast 96x96 PCR+Melt v2.pcl program. All primers were 
purchased from IDT and assay efficiency as well as melting and amplification curves for each 
assay were evaluated beforehand on a separate Biomark HD run with similar sorted B cell 
populations. All data were pre-analyzed with the Real-time PCR analysis software (Fluidigm), and 
Linear (Derivative) and User (Detectors) were used as settings to generate Ct values. A 
conservative Ct value of 25 was used as limit of detection (LOD). Relative gene expression was 
defined as a log2 value based on: log2 = LOD–Ct. All subsequent analysis of the gene expression 
data, including tSNE analysis and hierarchical clustering, were performed using R Studio.  
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T-bet siRNA knockdown: 
 Mature CD21-CD27- B cells from viremic HIV+ donors were transfected with 500 nM of 
control non-targeting or TBX21-specific On-target plus smart pool siRNAs (Thermo Fisher 
Scientific) using the Lonza nucleofection 96-well plate system, according to manufacturer 
specifications and as previously described (178). Cells were rapidly transferred to preheated 
complete medium (RPMI 1640-10% FBS) and incubated for 24 hours at 370C. Cell viability was 
evaluated by vital dye exclusion (Guava Technologies). TBX21 knockdown efficiency and impact 
on AICDA expression were evaluated by quantitative RT-PCR, as previously described (178). 
Briefly, total RNA was extracted using the RNeasy micro kit with on-column DNA digestion 
(Qiagen), according to manufacturer specifications. Total RNA was reverse transcribed and 
analyzed using TaqMan probe/primer mix (Applied Biosystems) by one-step quantitative PCR 
(Applied Biosystems 7500 system).  Data were normalized to the housekeeping gene POLRIIA 
by a comparative ΔΔCt method. 
 
Statistics: 
 Paired or unpaired t-tests (two-tailed) were used to compare two groups of data. When 
three or more groups were compared, one way ANOVA or repeated measures one way ANOVA, 
each combined with Tukey’s multiple comparisons test, were used. Correlative relationships were 
assessed using Spearman correlation. Error bars on all plots represent mean ± SEM. A P value 
P< 0.05 was considered significant. 
 
Study approval: 
 Written informed consent was obtained from study participants and blood/tissue samples 
were collected with institutional review board approval at each collecting institution: Oregon 
Health and Science University (IRB# 2470, IRB# 2832), University of Pennsylvania (IRB#809316, 
IRB# 815056), Case Western University (IRB# 10-09-12), University of Toronto (REB# 12-378), 
University of California San Francisco (IRB# 10-01330), Human Subjects Protection Branch 
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(RV217/WRAIR#1373), The United Republic of Tanzania Ministry of Health and Social Welfare 
(MRH/R.10/18/VOLL.VI/85), Tanzanian National Institute for Medical Research 
(NIMR/HQ/R.8aVol.1/2013), Royal Thai Army Medical Department (IRBRTA 1810/2558), Uganda 
National Council for Science and Technology– National HIV/AIDS Research Committee (ARC 
084), and Uganda National Council of Science and Technology (HS 688). This work was 
conducted in accordance with the principles expressed in the Declaration of Helsinki. 
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